CCR8

Note

CCR8 타겟 임상시험 모니터링

Visual Summary

Change History

NCT04895709

  • 2026-07-28 00:26:03 (Trial Update)
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-06-02` to `2026-06-29`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-06-04` to `2026-06-30`
    • Field `contactsLocationsModule.locations.[18]facility` changed from `BC Cancer Vancouver` to `Local Institution - 0030`
    • Field `contactsLocationsModule.locations.[18]status` changed from `RECRUITING` to `COMPLETED`
    • Field `contactsLocationsModule.locations.[22]facility` changed from `The Ottawa Hospital Cancer Centre` to `Local Institution - 0016`
    • Field `contactsLocationsModule.locations.[22]status` changed from `RECRUITING` to `COMPLETED`
    • Field removed: `root['contactsLocationsModule']['locations'][18]['contacts']`
    • Field removed: `root['contactsLocationsModule']['locations'][22]['contacts']`
  • 2026-06-05 03:53:46 (Trial Update)
    • Field `identificationModule.briefTitle` changed from `A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors` to `A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors`
    • Field `identificationModule.officialTitle` changed from `A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors` to `A Phase 1/2 Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors`
    • Field `statusModule.statusVerifiedDate` changed from `2026-04` to `2026-06`
    • Field `statusModule.primaryCompletionDateStruct.date` changed from `2028-07-07` to `2031-08-31`
    • Field `statusModule.completionDateStruct.date` changed from `2028-07-07` to `2031-08-31`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-04-08` to `2026-06-02`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-04-13` to `2026-06-04`
    • Field `descriptionModule.briefSummary` changed from `The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab or docetaxel in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with advanced solid tumors.` to `The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with advanced solid tumors.`
    • Field `designModule.designInfo.allocation` changed from `NON_RANDOMIZED` to `RANDOMIZED`
    • Field `designModule.enrollmentInfo.count` changed from `949` to `1109`
    • Field `outcomesModule.primaryOutcomes.[2]measure` changed from `Incidence of AEs meeting protocol defined dose-limiting toxicity (DLT) criteria` to `Number of deaths`
    • Field `eligibilityModule.eligibilityCriteria` changed from `Inclusion Criteria
      • Fresh pre-treatment and on-treatment tumor biopsy must be provided for biomarker analysis.
      • Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and at least 1 lesion accessible for biopsy. Fine needle biopsy, cytology, and bone lesion biopsies are not acceptable.
      • Eastern Cooperative Oncology Group Performance Status of 0 or 1.
      • Radiographically documented progressive disease on or after the most recent therapy.
      • Received standard-of-care therapies, (except for Part 1C, where participants with prior docetaxel use for the advanced/metastatic setting will be excluded), including an available programmed death (ligand)-1 inhibitor known to be effective in the tumor type for which they are being evaluated.
      • Advanced or metastatic disease and have received, be refractory to, not be a candidate for, or be intolerant of existing therapies known to provide clinical benefit for the condition of the participant.
    • Exclusion Criteria
      • Women` to `Inclusion Criteria
      • Fresh pre-treatment and on-treatment tumor biopsy must be provided for biomarker analysis.
      • Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and at least 1 lesion accessible for biopsy. Fine needle biopsy, cytology, and bone lesion biopsies are not acceptable.
      • Eastern Cooperative Oncology Group Performance Status of 0 or 1.
      • Radiographically documented progressive disease on or after the most recent therapy.
      • Received standard-of-care therapies, (except for Part 1C, 2C and 2D, where participants with prior docetaxel use for the advanced/metastatic setting will be excluded), including an available programmed death (ligand)-1 inhibitor known to be effective in the tumor type for which they are being evaluated.
      • Advanced or metastatic disease and have received, be refractory to, not be a candidate for, or be intolerant of existing therapies known to provide clinical benefit for the condition of the participant.
    • Exclusion Criter`
    • Field `contactsLocationsModule.locations.[24]facility` changed from `Universitaetsklinikum Ulm` to `Local Institution - 0044`
    • Field `contactsLocationsModule.locations.[24]status` changed from `RECRUITING` to `COMPLETED`
    • Field removed: `root['contactsLocationsModule']['locations'][24]['contacts']`
  • 2026-05-26 02:38:39 (Trial Update)
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-04-03` to `2026-04-08`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-04-06` to `2026-04-13`
    • Field `contactsLocationsModule.locations.[19]contacts.[0]phone` changed from `9053170886` to `905-387-9495`
  • 2026-04-07 02:32:47 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-02` to `2026-04`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-02-23` to `2026-04-03`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-02-25` to `2026-04-06`
    • Field `contactsLocationsModule.locations.[3]facility` changed from `Local Institution - 0062` to `University of Iowa`
    • Field `contactsLocationsModule.locations.[3]status` changed from `ACTIVE_NOT_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[7]facility` changed from `Local Institution - 0001` to `Providence Cancer Center Oncology and Hematology Care- Eastside`
    • Field `contactsLocationsModule.locations.[7]status` changed from `ACTIVE_NOT_RECRUITING` to `RECRUITING`
    • New field added: `root['contactsLocationsModule']['locations'][3]['contacts']`
    • New field added: `root['contactsLocationsModule']['locations'][7]['contacts']`
  • 2026-03-21 02:05:09 (Trial Update)
    • Field `contactsLocationsModule.locations.[39]city` changed from `Napoli` to `Naples`
    • Field `contactsLocationsModule.locations.[39]geoPoint.lat` changed from `40.87618` to `40.85216`
    • Field `contactsLocationsModule.locations.[39]geoPoint.lon` changed from `14.5195` to `14.26811`

NCT06479759

  • 2026-07-28 00:26:03 (Trial Update)
    • Field `statusModule.overallStatus` changed from `RECRUITING` to `UNKNOWN`
    • New field added: `root['statusModule']['lastKnownStatus']`

NCT06825494

  • 2026-03-14 02:07:19 (Trial Update)
    • Field `contactsLocationsModule.locations.[10]geoPoint.lat` changed from `32.99472` to `33.00524`
    • Field `contactsLocationsModule.locations.[10]geoPoint.lon` changed from `112.53278` to `112.54659`

NCT06821503

  • 2026-03-11 02:05:41 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2024-12` to `2025-12`
    • Field `statusModule.overallStatus` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `statusModule.startDateStruct.date` changed from `2025-02` to `2025-04-11`
    • Field `statusModule.startDateStruct.type` changed from `ESTIMATED` to `ACTUAL`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-02-13` to `2026-03-06`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-02-17` to `2026-03-10`
    • Field `eligibilityModule.eligibilityCriteria` changed from `Inclusion Criteria:
      • Age 18 or above.
      • The Eastern Cooperative Oncology Group (ECOG) physical fitness status score is 0-1 points.
      • There should be at least one measurable lesion.
      • All acute toxic reactions caused by previous anti-tumor treatments or surgical procedures have been relieved to grade 0-1 or to the levels specified in the inclusion/exclusion criteria.
      • Have sufficient organ and bone marrow function
      • Expected survival period ≥ 12 weeks
      • Infertility is defined as women who have reached menopause or have undergone bilateral oophorectomy with medical records. Male participants and female participants with fertility must agree to use one medically approved contraceptive measure during the trial period and within 6 months after the last administration of the trial drug or within 9 months after the last administration of chemotherapy drug (oxaliplatin) (whichever is later). The serum pregnancy test must be negative within 3 days before starting the study medication and not during lactation.
      • With my consent and signed informed consent form.
      • Patients diagnosed with Pancreatic ductal adenocarcinoma (PDAC) by pathology have evidence of advanced stage or metastasis that cannot be surgically removed.
      • Have not received systematic treatment for unresectable locally advanced or metastatic PDAC in the past
    • Exclusion Criteria:
      • Known High-frequency microsatellite instability (MSI-H)/deficient mismatch repair (dMMR).
      • There is uncontrolled or symptomatic active central nervous system metastasis, which can manifest as clinical symptoms, cerebral edema, spinal cord compression, cancerous meningitis, leptomeningeal disease, and/or progressive growth.
      • Within 14 days prior to enrollment, there were still uncontrollable pleural effusion and ascites despite treatment such as puncture and drainage; Pericardial effusion accompanied by clinical symptoms or moderate or above.
      • Within 14 days prior to enrollment, there is an unresolved biliary obstruction, or the clinical status has remained stable for less than 14 days after biliary stent implantation.
      • Participants' weight has decreased by more than 20% or their body mass index (BMI) is less than 18 kg/m ² within the first 2 months of enrollment.
      • Received the following treatments or medications before enrollment:
      1. Prior to enrollment, received treatment with C-C chemokine Receptor 8 (CCR8) antibodies, cytotoxic T-lymphocyte associated protein-4 (CTLA-4) antibodies, or other drugs that act on Tregs.
      1. Having undergone major surgery within 28 days prior to enrollment.
      1. Used immunosuppressive drugs within 14 days prior to enrollment.
      1. Vaccination with attenuated live vaccine should be administered within 28 days prior to enrollment or planned within the study period and 60 days after completion of study drug treatment.
      1. Received anti-tumor therapy (including chemotherapy, radiotherapy, immunotherapy, endocrine therapy, targeted therapy, biological therapy, or tumor embolization) within 28 days before enrollment.
      • Diagnosed with any other malignant tumor within the 5 years prior to enrollment.
      • There are any active, known or suspected autoimmune diseases present.
      • Within the first 3 months of enrollment, there have been significant clinical bleeding symptoms or clear bleeding tendencies; Arterial/venous thrombotic events that occurred within the first 6 months of enrollment.
      • Significant vascular disease occurred within the first 6 months of enrollment.
      • Severe, unhealed, or cracked wounds, as well as active ulcers or untreated fractures.
      • There is peripheral neuropathy of grade\>1 present.
      • Have experienced gastrointestinal perforation and/or gastrointestinal fistula within the 6 months prior to enrollment;
      • Within the 6 months prior to enrollment, there have been clinical signs or symptoms of intestinal obstruction and/or gastrointestinal obstruction.
      • Existence of interstitial lung disease, non infectious pneumonia, or uncontrolled systemic diseases.
      • Known to be allergic to the investigational drug or any of its excipients; Or have experienced severe allergic reactions to other monoclonal antibodies.
      • Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), untreated active hepatitis or co infection with hepatitis B and hepatitis C.
      • Clinical symptoms or diseases of the heart that have not been well controlled:
      • Systemic use of antibiotics for at least 7 days within the 28 days prior to enrollment, or unexplained fever\>38.5 °C during screening/before first administration.
      • Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.
      • Have participated in any other drug clinical studies within 4 weeks prior to enrollment, or have not had more than 5 half lives since the last study medication.
      • Known history of abuse or drug use of psychotropic substances.
      • There are other serious physical or mental illnesses or laboratory abnormalities that may increase the risk of participating in the study, or interfere with the study results, as well as patients who the researcher deems unsuitable to participate in this study.` to `Inclusion Criteria:
      • Age 18 or above.
      • The Eastern Cooperative Oncology Group (ECOG) physical fitness status score is 0-1 points.
      • There should be at least one measurable lesion.
      • All acute toxic reactions caused by previous anti-tumor treatments or surgical procedures have been relieved to grade 0-1 or to the levels specified in the inclusion/exclusion criteria.
      • Have sufficient organ and bone marrow function
      • Expected survival period ≥ 12 weeks
      • Infertility is defined as women who have reached menopause or have undergone bilateral oophorectomy with medical records. Male participants and female participants with fertility must agree to use one medically approved contraceptive measure during the trial period and within 6 months after the last administration of the trial drug or within 9 months after the last administration of chemotherapy drug (oxaliplatin) (whichever is later). The serum pregnancy test must be negative within 3 days before starting the study medication and not during lactation.
      • With my consent and signed informed consent form.
      • Patients with a pathological diagnosis of pancreatic cancer (ductal adenocarcinoma or adenocarcinoma) have evidence of advanced or metastatic disease that is not resectable.
      • Previously received no systemic treatment for unresectable locally advanced or metastatic pancreatic cancer.
    • Exclusion Criteria:
      • Known High-frequency microsatellite instability (MSI-H)/deficient mismatch repair (dMMR).
      • There is uncontrolled or symptomatic active central nervous system metastasis, which can manifest as clinical symptoms, cerebral edema, spinal cord compression, cancerous meningitis, leptomeningeal disease, and/or progressive growth.
      • Within 14 days prior to enrollment, there were still uncontrollable pleural effusion and ascites despite treatment such as puncture and drainage; Pericardial effusion accompanied by clinical symptoms or moderate or above.
      • Within 14 days prior to enrollment, there is an unresolved biliary obstruction, or the clinical status has remained stable for less than 14 days after biliary stent implantation.
      • Participants' weight has decreased by more than 20% or their body mass index (BMI) is less than 18 kg/m ² within the first 2 months of enrollment.
      • Received the following treatments or medications before enrollment:
      1. Prior to enrollment, received treatment with C-C chemokine Receptor 8 (CCR8) antibodies, cytotoxic T-lymphocyte associated protein-4 (CTLA-4) antibodies, or other drugs that act on Tregs.
      1. Having undergone major surgery within 28 days prior to enrollment.
      1. Used immunosuppressive drugs within 14 days prior to enrollment.
      1. Vaccination with attenuated live vaccine should be administered within 28 days prior to enrollment or planned within the study period and 60 days after completion of study drug treatment.
      1. Received anti-tumor therapy (including chemotherapy, radiotherapy, immunotherapy, endocrine therapy, targeted therapy, biological therapy, or tumor embolization) within 28 days before enrollment.
      • Diagnosed with any other malignant tumor within the 5 years prior to enrollment.
      • There are any active, known or suspected autoimmune diseases present.
      • Within the first 3 months of enrollment, there have been significant clinical bleeding symptoms or clear bleeding tendencies; Arterial/venous thrombotic events that occurred within the first 6 months of enrollment.
      • Significant vascular disease occurred within the first 6 months of enrollment.
      • Severe, unhealed, or cracked wounds, as well as active ulcers or untreated fractures.
      • There is peripheral neuropathy of grade\>1 present.
      • Have experienced gastrointestinal perforation and/or gastrointestinal fistula within the 6 months prior to enrollment;
      • Within the 6 months prior to enrollment, there have been clinical signs or symptoms of intestinal obstruction and/or gastrointestinal obstruction.
      • Existence of interstitial lung disease, non infectious pneumonia, or uncontrolled systemic diseases.
      • Known to be allergic to the investigational drug or any of its excipients; Or have experienced severe allergic reactions to other monoclonal antibodies.
      • Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), untreated active hepatitis or co infection with hepatitis B and hepatitis C.
      • Clinical symptoms or diseases of the heart that have not been well controlled:
      • Systemic use of antibiotics for at least 7 days within the 28 days prior to enrollment, or unexplained fever\>38.5 °C during screening/before first administration.
      • Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.
      • Have participated in any other drug clinical studies within 4 weeks prior to enrollment, or have not had more than 5 half lives since the last study medication.
      • Known history of abuse or drug use of psychotropic substances.
      • There are other serious physical or mental illnesses or laboratory abnormalities that may increase the risk of participating in the study, or interfere with the study results, as well as patients who the researcher deems unsuitable to participate in this study.`
    • Field `contactsLocationsModule.locations.[15]` changed from `{'facility': 'Tianjin Medical University Cancer Institute & Hospital', 'city': 'Tianjin', 'state': 'Tianjin Municipality', 'zip': '300000', 'country': 'China', 'contacts': [{'name': 'Jihui Hao, Doctor', 'role': 'CONTACT', 'phone': '18622221120', 'email': 'haojihui@tjmuch.com'}], 'geoPoint': {'lat': 39.14222, 'lon': 117.17667}}` to `{'facility': 'Tianjin Medical University Cancer Institute & Hospital', 'status': 'NOT_YET_RECRUITING', 'city': 'Tianjin', 'state': 'Tianjin Municipality', 'zip': '300000', 'country': 'China', 'contacts': [{'name': 'Jihui Hao, Doctor', 'role': 'CONTACT', 'phone': '18622221120', 'email': 'haojihui@tjmuch.com'}], 'geoPoint': {'lat': 39.14222, 'lon': 117.17667}}`
    • Field `contactsLocationsModule.locations.[3]` changed from `{'facility': 'Chongqing Qeneral Hospital', 'city': 'Chongqing', 'state': 'Chongqing Municipality', 'zip': '400013', 'country': 'China', 'contacts': [{'name': 'Huaizhi Wang, Doctor', 'role': 'CONTACT', 'phone': '13996950719', 'email': 'whuaizhi@qq.com'}], 'geoPoint': {'lat': 29.56026, 'lon': 106.55771}}` to `{'facility': 'Chongqing Qeneral Hospital', 'status': 'NOT_YET_RECRUITING', 'city': 'Chongqing', 'state': 'Chongqing Municipality', 'zip': '400013', 'country': 'China', 'contacts': [{'name': 'Huaizhi Wang, Doctor', 'role': 'CONTACT', 'phone': '13996950719', 'email': 'whuaizhi@qq.com'}], 'geoPoint': {'lat': 29.56026, 'lon': 106.55771}}`
    • Field `contactsLocationsModule.locations.[6]` changed from `{'facility': 'Huazhong University of Science and Technology Tongji Medical College of Huazhong University of Science and Technology', 'city': 'Wuhan', 'state': 'Hubei', 'zip': '430000', 'country': 'China', 'contacts': [{'name': 'Jun Xue, Doctor', 'role': 'CONTACT', 'phone': '15071258754', 'email': 'xjunion@126.com'}], 'geoPoint': {'lat': 30.58333, 'lon': 114.26667}}` to `{'facility': 'Huazhong University of Science and Technology Tongji Medical College of Huazhong University of Science and Technology', 'status': 'NOT_YET_RECRUITING', 'city': 'Wuhan', 'state': 'Hubei', 'zip': '430000', 'country': 'China', 'contacts': [{'name': 'Jun Xue, Doctor', 'role': 'CONTACT', 'phone': '15071258754', 'email': 'xjunion@126.com'}], 'geoPoint': {'lat': 30.58333, 'lon': 114.26667}}`
    • Field `contactsLocationsModule.locations.[8]` changed from `{'facility': "Jiangsu Provincial People's Hospital", 'city': 'Nanjing', 'state': 'Jiangsu', 'zip': '210000', 'country': 'China', 'contacts': [{'name': 'Kuirong Jiang, Doctor', 'role': 'CONTACT', 'phone': '15312995688', 'email': 'jiangkuirong@163.com'}], 'geoPoint': {'lat': 32.06167, 'lon': 118.77778}}` to `{'facility': "Jiangsu Provincial People's Hospital", 'status': 'NOT_YET_RECRUITING', 'city': 'Nanjing', 'state': 'Jiangsu', 'zip': '210000', 'country': 'China', 'contacts': [{'name': 'Kuirong Jiang, Doctor', 'role': 'CONTACT', 'phone': '15312995688', 'email': 'jiangkuirong@163.com'}], 'geoPoint': {'lat': 32.06167, 'lon': 118.77778}}`
    • Field `contactsLocationsModule.locations.[2]` changed from `{'facility': 'Beijing Cancer Hospital', 'city': 'Beijing', 'state': 'Beijing Municipality', 'zip': '100142', 'country': 'China', 'contacts': [{'name': 'Lin Shen, Doctor', 'role': 'CONTACT', 'phone': '010-88196561', 'email': 'doctorshenlin@sina.cn'}], 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}` to `{'facility': 'Beijing Cancer Hospital', 'status': 'RECRUITING', 'city': 'Beijing', 'state': 'Beijing Municipality', 'zip': '100142', 'country': 'China', 'contacts': [{'name': 'Lin Shen, Doctor', 'role': 'CONTACT', 'phone': '010-88196561', 'email': 'doctorshenlin@sina.cn'}], 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}`
    • Field `contactsLocationsModule.locations.[4]` changed from `{'facility': 'Harbin Medical University Cancer Hospital', 'city': 'Harbin', 'state': 'Heilongjiang', 'zip': '150081', 'country': 'China', 'contacts': [{'name': 'Zhiwei Li, Doctor', 'role': 'CONTACT', 'phone': '15004683651', 'email': 'lzhw0451@163.com'}], 'geoPoint': {'lat': 45.75, 'lon': 126.65}}` to `{'facility': 'Harbin Medical University Cancer Hospital', 'status': 'NOT_YET_RECRUITING', 'city': 'Harbin', 'state': 'Heilongjiang', 'zip': '150081', 'country': 'China', 'contacts': [{'name': 'Zhiwei Li, Doctor', 'role': 'CONTACT', 'phone': '15004683651', 'email': 'lzhw0451@163.com'}], 'geoPoint': {'lat': 45.75, 'lon': 126.65}}`
    • Field `contactsLocationsModule.locations.[12]` changed from `{'facility': "The First Affiliated Hospital of Xi'an Jiaotong University Medical College", 'city': "Xi'an", 'state': 'Shaanxi', 'zip': '710000', 'country': 'China', 'contacts': [{'name': 'Zheng Wu, Doctor', 'role': 'CONTACT', 'phone': '13609195898', 'email': 'woozheng@xjtu.edu.cn'}], 'geoPoint': {'lat': 34.25833, 'lon': 108.92861}}` to `{'facility': "The First Affiliated Hospital of Xi'an Jiaotong University Medical College", 'status': 'NOT_YET_RECRUITING', 'city': "Xi'an", 'state': 'Shaanxi', 'zip': '710000', 'country': 'China', 'contacts': [{'name': 'Zheng Wu, Doctor', 'role': 'CONTACT', 'phone': '13609195898', 'email': 'woozheng@xjtu.edu.cn'}], 'geoPoint': {'lat': 34.25833, 'lon': 108.92861}}`
    • Field `contactsLocationsModule.locations.[14]` changed from `{'facility': 'Tianjin Cancer Hospital Airport Hospital', 'city': 'Tianjin', 'state': 'Tianjin Municipality', 'zip': '300000', 'country': 'China', 'contacts': [{'name': 'Huikai Li, Doctor', 'role': 'CONTACT', 'phone': '18622228639', 'email': 'tjchlhk@126.com'}], 'geoPoint': {'lat': 39.14222, 'lon': 117.17667}}` to `{'facility': 'Tianjin Cancer Hospital Airport Hospital', 'status': 'NOT_YET_RECRUITING', 'city': 'Tianjin', 'state': 'Tianjin Municipality', 'zip': '300000', 'country': 'China', 'contacts': [{'name': 'Huikai Li, Doctor', 'role': 'CONTACT', 'phone': '18622228639', 'email': 'tjchlhk@126.com'}], 'geoPoint': {'lat': 39.14222, 'lon': 117.17667}}`
    • Field `contactsLocationsModule.locations.[13]` changed from `{'facility': 'The First Affiliated Hospital of Naval Medical University', 'city': 'Shanghai', 'state': 'Shanghai Municipality', 'zip': '200336', 'country': 'China', 'contacts': [{'name': 'Gang Jin, Doctor', 'role': 'CONTACT', 'phone': '13601635681', 'email': 'Jigang@sohu.com'}], 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}` to `{'facility': 'The First Affiliated Hospital of Naval Medical University', 'status': 'NOT_YET_RECRUITING', 'city': 'Shanghai', 'state': 'Shanghai Municipality', 'zip': '200336', 'country': 'China', 'contacts': [{'name': 'Gang Jin, Doctor', 'role': 'CONTACT', 'phone': '13601635681', 'email': 'Jigang@sohu.com'}], 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}`
    • Field `contactsLocationsModule.locations.[9]` changed from `{'facility': 'The First Affiliated Hospital of Nanchang University', 'city': 'Nanchang', 'state': 'Jiangxi', 'zip': '330006', 'country': 'China', 'contacts': [{'name': 'Yong Li, Doctor', 'role': 'CONTACT', 'phone': '15879155066', 'email': 'liyong1553@163.com'}], 'geoPoint': {'lat': 28.68396, 'lon': 115.85306}}` to `{'facility': 'The First Affiliated Hospital of Nanchang University', 'status': 'NOT_YET_RECRUITING', 'city': 'Nanchang', 'state': 'Jiangxi', 'zip': '330006', 'country': 'China', 'contacts': [{'name': 'Yong Li, Doctor', 'role': 'CONTACT', 'phone': '15879155066', 'email': 'liyong1553@163.com'}], 'geoPoint': {'lat': 28.68396, 'lon': 115.85306}}`
    • Field `contactsLocationsModule.locations.[5]` changed from `{'facility': 'The First Affiliated Hospital of Zhengzhou University', 'city': 'Zhengzhou', 'state': 'Henan', 'zip': '450000', 'country': 'China', 'contacts': [{'name': 'Feng Wang, Doctor', 'role': 'CONTACT', 'phone': '13938244776', 'email': 'fengw010@163.com'}, {'name': 'Aili Suo Suo, Doctor', 'role': 'CONTACT', 'phone': '18991232561', 'email': 'Ailisuo@mail.xjtu.edu.cn'}], 'geoPoint': {'lat': 34.75778, 'lon': 113.64861}}` to `{'facility': 'The First Affiliated Hospital of Zhengzhou University', 'status': 'NOT_YET_RECRUITING', 'city': 'Zhengzhou', 'state': 'Henan', 'zip': '450000', 'country': 'China', 'contacts': [{'name': 'Feng Wang, Doctor', 'role': 'CONTACT', 'phone': '13938244776', 'email': 'fengw010@163.com'}, {'name': 'Aili Suo Suo, Doctor', 'role': 'CONTACT', 'phone': '18991232561', 'email': 'Ailisuo@mail.xjtu.edu.cn'}], 'geoPoint': {'lat': 34.75778, 'lon': 113.64861}}`
    • Field `contactsLocationsModule.locations.[7]` changed from `{'facility': 'Jiangsu Cancer Hospital', 'city': 'Nanjing', 'state': 'Jiangsu', 'zip': '210000', 'country': 'China', 'contacts': [{'name': 'Xiaofeng Sun, Master', 'role': 'CONTACT', 'phone': '13505156959', 'email': 'jssxfgcp@163.com'}], 'geoPoint': {'lat': 32.06167, 'lon': 118.77778}}` to `{'facility': 'Jiangsu Cancer Hospital', 'status': 'NOT_YET_RECRUITING', 'city': 'Nanjing', 'state': 'Jiangsu', 'zip': '210000', 'country': 'China', 'contacts': [{'name': 'Xiaofeng Sun, Master', 'role': 'CONTACT', 'phone': '13505156959', 'email': 'jssxfgcp@163.com'}], 'geoPoint': {'lat': 32.06167, 'lon': 118.77778}}`
    • Field `contactsLocationsModule.locations.[10]` changed from `{'facility': 'The First Affiliated Hospital of China Medical University', 'city': 'Shenyang', 'state': 'Liaoning', 'zip': '110000', 'country': 'China', 'contacts': [{'name': 'Xiujuan Qu, Doctor', 'role': 'CONTACT', 'phone': '13604031355', 'email': 'qu_xiujuan@hotmail.com'}], 'geoPoint': {'lat': 41.79222, 'lon': 123.43278}}` to `{'facility': 'The First Affiliated Hospital of China Medical University', 'status': 'NOT_YET_RECRUITING', 'city': 'Shenyang', 'state': 'Liaoning', 'zip': '110000', 'country': 'China', 'contacts': [{'name': 'Xiujuan Qu, Doctor', 'role': 'CONTACT', 'phone': '13604031355', 'email': 'qu_xiujuan@hotmail.com'}], 'geoPoint': {'lat': 41.79222, 'lon': 123.43278}}`
    • Field `contactsLocationsModule.locations.[1]` changed from `{'facility': 'Cancer Hospital Chinese Academy of Medical Science', 'city': 'Beijing', 'state': 'Beijing Municipality', 'zip': '100021', 'country': 'China', 'contacts': [{'name': 'Yongkun Sun, Doctor', 'role': 'CONTACT', 'phone': '13141276041', 'email': 'hsunyk@126.com'}], 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}` to `{'facility': 'Cancer Hospital Chinese Academy of Medical Science', 'status': 'NOT_YET_RECRUITING', 'city': 'Beijing', 'state': 'Beijing Municipality', 'zip': '100021', 'country': 'China', 'contacts': [{'name': 'Yongkun Sun, Doctor', 'role': 'CONTACT', 'phone': '13141276041', 'email': 'hsunyk@126.com'}], 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}`
    • Field `contactsLocationsModule.locations.[11]` changed from `{'facility': "The Sixth People's Hospital of Shenyang", 'city': 'Shenyang', 'state': 'Liaoning', 'zip': '110002', 'country': 'China', 'contacts': [{'name': 'Jin Xu, Doctor', 'role': 'CONTACT', 'phone': '13236666950', 'email': 'xvjin2024@sina.com'}], 'geoPoint': {'lat': 41.79222, 'lon': 123.43278}}` to `{'facility': "The Sixth People's Hospital of Shenyang", 'status': 'NOT_YET_RECRUITING', 'city': 'Shenyang', 'state': 'Liaoning', 'zip': '110002', 'country': 'China', 'contacts': [{'name': 'Jin Xu, Doctor', 'role': 'CONTACT', 'phone': '13236666950', 'email': 'xvjin2024@sina.com'}], 'geoPoint': {'lat': 41.79222, 'lon': 123.43278}}`
    • Field `contactsLocationsModule.locations.[0]` changed from `{'facility': 'Peking Union Medical College Hospital', 'city': 'Beijing', 'state': 'Beijing Municipality', 'zip': '100005', 'country': 'China', 'contacts': [{'name': 'Xicheng Wang, Doctor', 'role': 'CONTACT', 'phone': '13439563949', 'email': 'xicheng_wang@hotmail.com'}], 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}` to `{'facility': 'Peking Union Medical College Hospital', 'status': 'NOT_YET_RECRUITING', 'city': 'Beijing', 'state': 'Beijing Municipality', 'zip': '100005', 'country': 'China', 'contacts': [{'name': 'Xicheng Wang, Doctor', 'role': 'CONTACT', 'phone': '13439563949', 'email': 'xicheng_wang@hotmail.com'}], 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}`

NCT05005403

  • 2026-06-24 14:19:39 (Trial Update)
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-06-15` to `2026-06-19`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-06-16` to `2026-06-23`
  • 2026-06-17 04:13:30 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-05` to `2026-06`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-05-11` to `2026-06-15`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-05-13` to `2026-06-16`
    • Field `contactsLocationsModule.locations.[13]facility` changed from `Next Oncology - Irving /ID# 276254` to `Next Oncology Dallas /ID# 276254`
    • Field `contactsLocationsModule.locations.[21]city` changed from `Kfar Saba` to `Kefar Sava`
    • Field `contactsLocationsModule.locations.[40]city` changed from `Taipei City` to `Taipei`
    • New field added: `root['contactsLocationsModule']['locations'][27]['state']`
    • New field added: `root['contactsLocationsModule']['locations'][40]['geoPoint']`
    • Field removed: `root['contactsLocationsModule']['locations'][40]['state']`
  • 2026-06-16 04:16:41 (Trial Update)
    • Field removed: `root['referencesModule']`
  • 2026-05-26 02:38:39 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-03` to `2026-05`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-03-30` to `2026-05-11`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-04-03` to `2026-05-13`
    • Field `contactsLocationsModule.locations.[33]status` changed from `RECRUITING` to `COMPLETED`
    • Field `contactsLocationsModule.locations.[35]geoPoint.lat` changed from `35.54127` to `36.4052`
    • Field `contactsLocationsModule.locations.[35]geoPoint.lon` changed from `127.39683` to `127.7548`
  • 2026-04-04 02:21:51 (Trial Update)
    • Field `identificationModule.briefTitle` changed from `Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab` to `Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan`
    • Field `identificationModule.officialTitle` changed from `A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors With Azirkitug (ABBV-514) as a Single Agent and in Combination With Budigalimab or Bevacizumab` to `A Global First-in-Human Study in NSCLC, HNSCC, and Solid Tumors With Azirkitug as a Single Agent and in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan`
    • Field `statusModule.statusVerifiedDate` changed from `2025-10` to `2026-03`
    • Field `statusModule.primaryCompletionDateStruct.date` changed from `2026-07` to `2027-07`
    • Field `statusModule.completionDateStruct.date` changed from `2027-06` to `2027-07`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-10-27` to `2026-03-30`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-10-28` to `2026-04-03`
    • Field `descriptionModule.briefSummary` changed from `Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. Head and Neck Squamous Cell Carcinoma (HNSCC) is a solid tumor, a disease in which cancer cells form in the tissues of the head and neck. The purpose of this study is to assess adverse events and pharmacokinetics of Azirkitug (ABBV-514) as a monotherapy and in combination with Budigalimab or Bevacizumab,.
    • Bevacizumab is an approved product, while Budigalimab and Azirkitug (ABBV-514) are investigational drugs being developed for the treatment of NSCLC, HNSCC, and other solid tumors. Study doctors put the participants in groups called treatment arms. The maximum-tolerated dose (MTD)/maximum administered dose (MAD) of Azirkitug (ABBV-514) will be explored. Each treatment arm receives a different dose of Azirkitug (ABBV-514) in monotherapy and in combination with Budigalimab or Bevacizumab. Approximately 512 adult participants will be enrolled in the study across approximately 80 sites worldwide.
    • Participants will receive Azirkitug (ABBV-514) as a monotherapy or in combination with Budigalimab or Bevacizumab as an Intravenous (IV) Infusion for an estimated treatment period of up to 2 years.
    • There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.` to `Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. Head and Neck Squamous Cell Carcinoma (HNSCC) is a solid tumor, a disease in which cancer cells form in the tissues of the head and neck. The purpose of this study is to assess adverse events and pharmacokinetics of azirkitug as a monotherapy and in combination with budigalimab, bevacizumab, or telisotuzumab adizutecan.
    • Bevacizumab is an approved product, while budigalimab, azirkitug, and telisotuzumab adizutecan are investigational drugs being developed for the treatment of NSCLC, HNSCC, and other solid tumors. Study doctors put the participants in groups called treatment arms. The maximum-tolerated dose (MTD)/maximum administered dose (MAD) of azirkitug will be explored. Each treatment arm receives a different dose of azirkitug in monotherapy and in combination with budigalimab, bevacizumab, or telisotuzumab adizutecan. Approximately 694 adult participants will be enrolled in the study across approximately 80 sites worldwide.
    • Participants will receive azirkitug as a monotherapy or in combination with budigalimab, bevacizumab, or telisotuzumab adizutecan as an Intravenous (IV) Infusion for an estimated treatment period of up to 2 years.
    • There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.`
    • Field `designModule.enrollmentInfo.count` changed from `512` to `694`
    • Field `eligibilityModule.eligibilityCriteria` changed from `Inclusion Criteria:
      • Pre Treatment biopsy or archive tissue within 6 months without intervening treatment
      • Eastern Cooperative Oncology Group (ECOG) performance status of \<=1
      • Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST)
      • Laboratory values meeting criteria outlined in the protocol
      • NSCLC - Advanced or metastatic progressed on standard of care (SOC) including chemotherapy and prior anti-PD-(L)1 antibody (separately or in combination). Actionable gene alterations are eligible if failed targeted therapeutic options.
      • HSNCC - Advanced/metastatic progressed on platinum and PD-1/PD-LI in recurrent or metastatic setting.
      • Micro Satellite Stable Colorectal Cancer (MSS-CRC) - Progressed on Oxaliplatin, Irinotecan, a fluoropyrimidine, anti-EGFR, VEGF or VEGFR therapies, TAS-102, Regorafenib and not MSI-h or MMR-deficient
      • Gastric and Gastroesophageal Junction adenocarcinoma (GEA) - Advanced/metastatic progressed on at least 1 prior cytotoxic chemotherapeutic regimen and if applicable immune checkpoint inhibitor and/or HER2 therapy
      • High-Grade Serous Ovarian Cancer (HGSOC) - Progressed serous epithelial ovarian, fallopian tube or primary peritoneal cancer post SOC and not eligible for surgical resection. Platinum resistant cannot have \>5 lines of prior therapy.
      • Pancreatic Adenocarcinoma (PDAC) - Advanced/metastatic progressed after SOC. Includes adenosquamous carcinoma and post-Whipple.
      • Triple Negative Breast Cancer (TNBC) - Progressed after \>1 systemic therapy that must have included taxane and treatment naïve to immunotherapy targeting T-cell co-stimulation
    • Exclusion Criteria:
      • Pancreatic Ductal Adenocarcinoma (PDAC) - Excludes neuroendocrine or acinar pancreatic carcinoma and participants with coagulopathy or at risk of or history of Deep vein thrombosis (DVT)/PE
      • No major surgery within 28 days prior to dosing
      • No active autoimmune/immunodeficiency disease with limited exceptions
      • Combination treatment excludes participants treated with anti-programmed cell death protein 1(PD-1)/Programmed cell death ligand 1 (PD-L1) who had immune mediated toxicity G3 or greater, interstitial lung disease, or hypersensitivity Combination treatment may also require no significant cardiac deficiencies and/or events
      • Pregnancy
      • Excluded medications include anticancer therapy within 5 half-live or 28 days (whichever is shorter), agent targeting Chemokine Receptor (CCR)8, live vaccines, immunosuppressive medication with limited exceptions` to `Inclusion Criteria:
      • Pre Treatment biopsy or archive tissue within 6 months without intervening treatment
      • Eastern Cooperative Oncology Group (ECOG) performance status of \<= 0 or 1 and a life expectancy of \>= 3 months.
      • Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST)
      • Laboratory values meeting criteria outlined in the protocol
      • NSCLC - Advanced or metastatic progressed on standard of care (SOC) including chemotherapy and prior anti-PD-(L)1 antibody (separately or in combination). Actionable gene alterations are eligible if failed targeted therapeutic options.
      • HSNCC - Advanced/metastatic progressed on platinum and PD-1/PD-LI in recurrent or metastatic setting.
      • Micro Satellite Stable Colorectal Cancer (MSS-CRC) - Progressed on Oxaliplatin, Irinotecan, a fluoropyrimidine, anti-EGFR, VEGF or VEGFR therapies, BRAFV600E or HER2, other targetable mutations targeted with locally approved therapy, TAS-102, Regorafenib and not MSI-h or MMR-deficient
      • Gastric and Gastroesophageal Junction adenocarcinoma (GEA) - Advanced/metastatic progressed on at least 1 prior cytotoxic chemotherapeutic regimen and if applicable immune checkpoint inhibitor and/or HER2 therapy
      • High-Grade Serous Ovarian Cancer (HGSOC) - Progressed serous epithelial ovarian, fallopian tube or primary peritoneal cancer post SOC and not eligible for surgical resection. Platinum resistant cannot have \>5 lines of prior therapy.
      • Pancreatic Adenocarcinoma (PDAC) - Advanced/metastatic progressed after SOC. Includes adenosquamous carcinoma and post-Whipple.
      • Triple Negative Breast Cancer (TNBC) - Progressed after 1 or 2 systemic therapy that must have included taxane and treatment naïve to immunotherapy targeting T-cell co-stimulation
    • Exclusion Criteria:
      • Pancreatic Ductal Adenocarcinoma (PDAC) - Excludes neuroendocrine or acinar pancreatic carcinoma and participants with coagulopathy or at risk of or history of Deep vein thrombosis (DVT)/PE
      • No major surgery within 28 days prior to dosing
      • No active autoimmune/immunodeficiency disease with limited exceptions
      • Combination treatment excludes participants treated with anti-programmed cell death protein 1(PD-1)/Programmed cell death ligand 1 (PD-L1) who had immune mediated toxicity G3 or greater, interstitial lung disease, or hypersensitivity Combination treatment may also require no significant cardiac deficiencies and/or events
      • Pregnancy
      • Excluded medications include anticancer therapy within 5 half-live or 28 days (whichever is shorter), agent targeting Chemokine Receptor (CCR)8, live vaccines, immunosuppressive medication with limited exceptions`
    • Field `contactsLocationsModule.locations.[17]facility` changed from `Rabin Medical Center /ID# 250497` to `Rabin Medical Center. /ID# 250497`
    • Field `armsInterventionsModule.armGroups.[11]` changed from `{'label': 'Part 8 Dose Escalation: Azirkitug (ABBV-514) + Bevacizumab', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive Azirkitug (ABBV-514) in combination with bevacizumab.', 'interventionNames': ['Drug: Azirkitug', 'Drug: Bevacizumab']}` to `{'label': 'Part 7 Dose Expansion: Azirkitug + Budigalimab', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive Azirkitug at recommended dose determined in Dose Escalation portion in combination with budigalimab.', 'interventionNames': ['Drug: Azirkitug', 'Drug: Budigalimab']}`
    • Field `armsInterventionsModule.armGroups.[8]` changed from `{'label': 'Part 5 Dose Expansion: Azirkitug (ABBV-514) + Budigalimab', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive Azirkitug (ABBV-514) at recommended dose determined in Dose Escalation portion in combination with budigalimab.', 'interventionNames': ['Drug: Azirkitug', 'Drug: Budigalimab']}` to `{'label': 'Part 4 Dose Optimization & Randomization Azirkitug+Budigalimab', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive Azirkitug in combination with budigalimab.', 'interventionNames': ['Drug: Azirkitug', 'Drug: Budigalimab']}`
    • Field `armsInterventionsModule.armGroups.[2]` changed from `{'label': 'Part 2 Dose Expansion: Azirkitug (ABBV-514)', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive Azirkitug (ABBV-514) at recommended dose determined in Dose Escalation portion.', 'interventionNames': ['Drug: Azirkitug']}` to `{'label': 'Part 2 Dose Expansion: Azirkitug', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive Azirkitug at recommended dose determined in Dose Escalation portion.', 'interventionNames': ['Drug: Azirkitug']}`
    • Field `armsInterventionsModule.interventions.[2]` changed from `{'type': 'DRUG', 'name': 'Bevacizumab', 'description': 'Intravenous (IV) Infusion', 'armGroupLabels': ['Part 8 Dose Escalation: Azirkitug (ABBV-514) + Bevacizumab', 'Part 8 Dose Expansion: Azirkitug (ABBV-514) + Bevacizumab']}` to `{'type': 'DRUG', 'name': 'Bevacizumab', 'description': 'Intravenous (IV) Infusion', 'armGroupLabels': ['Part 8 Dose Expansion: Azirkitug + Bevacizumab', 'Part 8 Safety Lead In: Azirkitug + Bevacizumab']}`
    • Field `armsInterventionsModule.armGroups.[9]` changed from `{'label': 'Part 6 Dose Expansion: Azirkitug (ABBV-514) + Budigalimab', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive Azirkitug (ABBV-514) at recommended dose determined in Dose Escalation portion in combination with budigalimab.', 'interventionNames': ['Drug: Azirkitug', 'Drug: Budigalimab']}` to `{'label': 'Part 5 Dose Expansion: Azirkitug + Budigalimab', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive Azirkitug at recommended dose determined in Dose Escalation portion in combination with budigalimab.', 'interventionNames': ['Drug: Azirkitug', 'Drug: Budigalimab']}`
    • Field `armsInterventionsModule.armGroups.[4]` changed from `{'label': 'Part 3 Dose Expansion: Azirkitug (ABBV-514) + Budigalimab', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive Azirkitug (ABBV-514) at recommended dose determined in Dose Escalation portion in combination with budigalimab.', 'interventionNames': ['Drug: Azirkitug', 'Drug: Budigalimab']}` to `{'label': 'Part 3 Dose Expansion: Azirkitug + Budigalimab', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive Azirkitug at recommended dose determined in Dose Escalation portion in combination with budigalimab.', 'interventionNames': ['Drug: Azirkitug', 'Drug: Budigalimab']}`
    • Field `armsInterventionsModule.interventions.[0]` changed from `{'type': 'DRUG', 'name': 'Azirkitug', 'description': 'Intravenous (IV) Infusion', 'armGroupLabels': ['Part 1 Dose Escalation: Azirkitug (ABBV-514)', 'Part 1 Dose Escalation: Azirkitug (ABBV-514) + Budigalimab', 'Part 2 Dose Expansion: Azirkitug (ABBV-514)', 'Part 2 Dose Expansion: Azirkitug (ABBV-514) + Budigalimab', 'Part 3 Dose Expansion: Azirkitug (ABBV-514) + Budigalimab', 'Part 4 Dose Expansion: Azirkitug (ABBV-514)', 'Part 4 Dose Expansion: Azirkitug (ABBV-514) + Budigalimab', 'Part 5 Dose Expansion: Azirkitug (ABBV-514)', 'Part 5 Dose Expansion: Azirkitug (ABBV-514) + Budigalimab', 'Part 6 Dose Expansion: Azirkitug (ABBV-514) + Budigalimab', 'Part 7 Dose Expansion: Azirkitug (ABBV-514) + Budigalimab', 'Part 8 Dose Escalation: Azirkitug (ABBV-514) + Bevacizumab', 'Part 8 Dose Expansion: Azirkitug (ABBV-514) + Bevacizumab', 'Part 9 Dose Expansion: Azirkitug (ABBV-514) + Budigalimab'], 'otherNames': ['ABBV-514']}` to `{'type': 'DRUG', 'name': 'Azirkitug', 'description': 'Intravenous (IV) Infusion', 'armGroupLabels': ['Part 1 Dose Escalation: Azirkitug', 'Part 1 Dose Escalation: Azirkitug + Budigalimab', 'Part 10 Dose Expansion: Azirkitug+Telisotuzumab Adizutecan', 'Part 10 Safety Lead In: Azirkitug + Telisotuzumab Adizutecan', 'Part 2 Dose Expansion: Azirkitug', 'Part 2 Dose Expansion: Azirkitug + Budigalimab', 'Part 3 Dose Expansion: Azirkitug + Budigalimab', 'Part 4 Dose Expansion: Azirkitug', 'Part 4 Dose Expansion: Azirkitug + Budigalimab', 'Part 4 Dose Optimization & Randomization Azirkitug+Budigalimab', 'Part 4 Dose Optimization and Randomization: Azirkitug', 'Part 5 Dose Expansion: Azirkitug + Budigalimab', 'Part 6 Dose Expansion: Azirkitug + Budigalimab', 'Part 7 Dose Expansion: Azirkitug + Budigalimab', 'Part 8 Dose Expansion: Azirkitug + Bevacizumab', 'Part 8 Safety Lead In: Azirkitug + Bevacizumab', 'Part 9 Dose Expansion: Azirkitug + Budigalimab']}`
    • Field `armsInterventionsModule.armGroups.[5]` changed from `{'label': 'Part 4 Dose Expansion: Azirkitug (ABBV-514)', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive Azirkitug (ABBV-514) at recommended dose determined in Dose Escalation portion.', 'interventionNames': ['Drug: Azirkitug']}` to `{'label': 'Part 4 Dose Expansion: Azirkitug', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive Azirkitug at recommended dose determined in Dose Escalation portion.', 'interventionNames': ['Drug: Azirkitug']}`
    • Field `outcomesModule.primaryOutcomes.[1]` changed from `{'measure': 'Maximum Observed Serum Concentration (Cmax) of ABBV-514', 'description': 'Maximum Observed Serum Concentration (Cmax) of of ABBV-514.', 'timeFrame': 'Up to 2 Years'}` to `{'measure': 'Maximum Observed Serum Concentration (Cmax) of Azirkitug', 'description': 'Maximum Observed Serum Concentration (Cmax) of azirkitug.', 'timeFrame': 'Up to 2 Years'}`
    • Field `armsInterventionsModule.armGroups.[7]` changed from `{'label': 'Part 5 Dose Expansion: Azirkitug (ABBV-514)', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive Azirkitug (ABBV-514) at recommended dose determined in Dose Escalation portion.', 'interventionNames': ['Drug: Azirkitug']}` to `{'label': 'Part 4 Dose Optimization and Randomization: Azirkitug', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive Azirkitug at recommended dose determined in Dose Escalation portion.', 'interventionNames': ['Drug: Azirkitug']}`
    • Field `armsInterventionsModule.armGroups.[10]` changed from `{'label': 'Part 7 Dose Expansion: Azirkitug (ABBV-514) + Budigalimab', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive Azirkitug (ABBV-514) at recommended dose determined in Dose Escalation portion in combination with budigalimab.', 'interventionNames': ['Drug: Azirkitug', 'Drug: Budigalimab']}` to `{'label': 'Part 6 Dose Expansion: Azirkitug + Budigalimab', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive Azirkitug at recommended dose determined in Dose Escalation portion in combination with budigalimab.', 'interventionNames': ['Drug: Azirkitug', 'Drug: Budigalimab']}`
    • Field `outcomesModule.primaryOutcomes.[4]` changed from `{'measure': 'Area Under the Serum Concentration Versus Time Curve (AUC) of ABBV-514', 'description': 'Area under the serum concentration versus time curve (AUC) of ABBV-514.', 'timeFrame': 'Up to 2 Years'}` to `{'measure': 'Area Under the Serum Concentration Versus Time Curve (AUC) of Azirkitug', 'description': 'Area under the serum concentration versus time curve (AUC) of azirkitug.', 'timeFrame': 'Up to 2 Years'}`
    • Field `outcomesModule.primaryOutcomes.[2]` changed from `{'measure': 'Time to Maximum Observed Serum Concentration (Tmax) of ABBV-514', 'description': 'Time to maximum Observed Serum Concentration (Tmax) of of ABBV-514.', 'timeFrame': 'Up to 2 Years'}` to `{'measure': 'Time to Maximum Observed Serum Concentration (Tmax) of Azirkitug', 'description': 'Time to maximum Observed Serum Concentration (Tmax) of azirkitug.', 'timeFrame': 'Up to 2 Years'}`
    • Field `armsInterventionsModule.interventions.[1]` changed from `{'type': 'DRUG', 'name': 'Budigalimab', 'description': 'Intravenous (IV) Infusion', 'armGroupLabels': ['Part 1 Dose Escalation: Azirkitug (ABBV-514) + Budigalimab', 'Part 2 Dose Expansion: Azirkitug (ABBV-514) + Budigalimab', 'Part 3 Dose Expansion: Azirkitug (ABBV-514) + Budigalimab', 'Part 4 Dose Expansion: Azirkitug (ABBV-514) + Budigalimab', 'Part 5 Dose Expansion: Azirkitug (ABBV-514) + Budigalimab', 'Part 6 Dose Expansion: Azirkitug (ABBV-514) + Budigalimab', 'Part 7 Dose Expansion: Azirkitug (ABBV-514) + Budigalimab', 'Part 9 Dose Expansion: Azirkitug (ABBV-514) + Budigalimab'], 'otherNames': ['ABBV-181']}` to `{'type': 'DRUG', 'name': 'Budigalimab', 'description': 'Intravenous (IV) Infusion', 'armGroupLabels': ['Part 1 Dose Escalation: Azirkitug + Budigalimab', 'Part 2 Dose Expansion: Azirkitug + Budigalimab', 'Part 3 Dose Expansion: Azirkitug + Budigalimab', 'Part 4 Dose Expansion: Azirkitug + Budigalimab', 'Part 4 Dose Optimization & Randomization Azirkitug+Budigalimab', 'Part 5 Dose Expansion: Azirkitug + Budigalimab', 'Part 6 Dose Expansion: Azirkitug + Budigalimab', 'Part 7 Dose Expansion: Azirkitug + Budigalimab', 'Part 9 Dose Expansion: Azirkitug + Budigalimab']}`
    • Field `outcomesModule.primaryOutcomes.[3]` changed from `{'measure': 'Terminal Elimination Half-Life (t1/2) of ABBV-514', 'description': 'Terminal elimination half-life (t1/2) of ABBV-514.', 'timeFrame': 'Up to 2 Years'}` to `{'measure': 'Terminal Elimination Half-Life (t1/2) of Azirkitug', 'description': 'Terminal elimination half-life (t1/2) of azirkitug.', 'timeFrame': 'Up to 2 Years'}`
    • Field `armsInterventionsModule.armGroups.[12]` changed from `{'label': 'Part 8 Dose Expansion: Azirkitug (ABBV-514) + Bevacizumab', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive Azirkitug (ABBV-514) at recommended dose determined in Dose Escalation portion in combination with bevacizumab.', 'interventionNames': ['Drug: Azirkitug', 'Drug: Bevacizumab']}` to `{'label': 'Part 8 Safety Lead In: Azirkitug + Bevacizumab', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive Azirkitug in combination with bevacizumab.', 'interventionNames': ['Drug: Azirkitug', 'Drug: Bevacizumab']}`
    • Field `armsInterventionsModule.armGroups.[0]` changed from `{'label': 'Part 1 Dose Escalation: Azirkitug (ABBV-514)', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive Azirkitug (ABBV-514).', 'interventionNames': ['Drug: Azirkitug']}` to `{'label': 'Part 1 Dose Escalation: Azirkitug', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive Azirkitug.', 'interventionNames': ['Drug: Azirkitug']}`
    • Field `armsInterventionsModule.armGroups.[1]` changed from `{'label': 'Part 1 Dose Escalation: Azirkitug (ABBV-514) + Budigalimab', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive Azirkitug (ABBV-514) in combination with budigalimab.', 'interventionNames': ['Drug: Azirkitug', 'Drug: Budigalimab']}` to `{'label': 'Part 1 Dose Escalation: Azirkitug + Budigalimab', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive Azirkitug in combination with budigalimab.', 'interventionNames': ['Drug: Azirkitug', 'Drug: Budigalimab']}`
    • Field `armsInterventionsModule.armGroups.[3]` changed from `{'label': 'Part 2 Dose Expansion: Azirkitug (ABBV-514) + Budigalimab', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive Azirkitug (ABBV-514) at recommended dose determined in Dose Escalation portion in combination with budigalimab.', 'interventionNames': ['Drug: Azirkitug', 'Drug: Budigalimab']}` to `{'label': 'Part 2 Dose Expansion: Azirkitug + Budigalimab', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive Azirkitug at recommended dose determined in Dose Escalation portion in combination with budigalimab.', 'interventionNames': ['Drug: Azirkitug', 'Drug: Budigalimab']}`
    • Field `armsInterventionsModule.armGroups.[13]` changed from `{'label': 'Part 9 Dose Expansion: Azirkitug (ABBV-514) + Budigalimab', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive Azirkitug (ABBV-514) at recommended dose determined in Dose Escalation portion in combination with budigalimab.', 'interventionNames': ['Drug: Azirkitug', 'Drug: Budigalimab']}` to `{'label': 'Part 8 Dose Expansion: Azirkitug + Bevacizumab', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive Azirkitug at recommended dose determined in Dose Escalation portion in combination with bevacizumab.', 'interventionNames': ['Drug: Azirkitug', 'Drug: Bevacizumab']}`
    • Field `outcomesModule.primaryOutcomes.[5]` changed from `{'measure': 'Antidrug Antibody (ADA)', 'description': 'Incidence and concentration of anti-drug antibodies.', 'timeFrame': 'Up to 2 Years'}` to `{'measure': 'Azirkitug Antidrug Antibody (ADA)', 'description': 'Incidence and concentration of azirkitug anti-drug antibodies.', 'timeFrame': 'Up to 2 Years'}`
    • Field `outcomesModule.primaryOutcomes.[6]` changed from `{'measure': 'Neutralizing Antidrug Antibody (nADA)', 'description': 'Incidence and concentration of neutralizing anti-drug antibodies.', 'timeFrame': 'Up to 2 Years'}` to `{'measure': 'Azirkitug Neutralizing Antidrug Antibody (nADA)', 'description': 'Incidence and concentration of azirkitug neutralizing anti-drug antibodies.', 'timeFrame': 'Up to 2 Years'}`
    • Field `armsInterventionsModule.armGroups.[6]` changed from `{'label': 'Part 4 Dose Expansion: Azirkitug (ABBV-514) + Budigalimab', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive Azirkitug (ABBV-514) at recommended dose determined in Dose Escalation portion in combination with budigalimab.', 'interventionNames': ['Drug: Azirkitug', 'Drug: Budigalimab']}` to `{'label': 'Part 4 Dose Expansion: Azirkitug + Budigalimab', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive Azirkitug in combination with budigalimab.', 'interventionNames': ['Drug: Azirkitug', 'Drug: Budigalimab']}`
    • New field added: `root['referencesModule']`

NCT05581004

  • 2026-07-28 00:26:03 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-06` to `2026-07`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-06-05` to `2026-07-03`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-06-09` to `2026-07-07`
    • Field `contactsLocationsModule.locations.[10]facility` changed from `South Texas Accelerated Research Therapeutics (START)` to `IDS (IDS) Pharmacist South Texas Accelerated Resear Therapeutics, LLC START`
    • Field `contactsLocationsModule.locations.[10]zip` changed from `98229` to `78229`
    • Field `contactsLocationsModule.locations.[22]city` changed from `Pavlos Melas` to `N. Efkapria-Pavlos Melas`
    • Field `contactsLocationsModule.locations.[30]facility` changed from `ICO Hospitalet- Hospital Duran i Reynals` to `ICO l?Hospitalet ? Hospital Duran i Reynals`
  • 2026-06-10 03:50:42 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-05` to `2026-06`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-05-08` to `2026-06-05`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-05-11` to `2026-06-09`
    • New field added: `root['referencesModule']`
  • 2026-05-26 02:38:39 (Trial Update)
    • Field `identificationModule.briefTitle` changed from `A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors` to `A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors`
    • Field `identificationModule.officialTitle` changed from `A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors` to `A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors`
    • Field `statusModule.statusVerifiedDate` changed from `2026-02` to `2026-05`
    • Field `statusModule.primaryCompletionDateStruct.date` changed from `2027-02-28` to `2028-07-31`
    • Field `statusModule.completionDateStruct.date` changed from `2027-02-28` to `2028-07-31`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-02-16` to `2026-05-08`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-02-17` to `2026-05-11`
    • Field `descriptionModule.briefSummary` changed from `This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of RO7502175 when administered as a single agent and in combination with atezolizumab or pembrolizumab in adult participants with locally advanced or metastatic solid tumors, including non-small-cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, triple-negative breast cancer (TNBC), esophageal cancer, gastric cancer, cervical cancer, colorectal cancer (CRC), urothelial carcinoma (UC), clear cell renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Participants will be enrolled in 2 stages: dose escalation and dose expansion.` to `This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of enzelkitug when administered as a single agent and in combination with atezolizumab or pembrolizumab in adult participants with locally advanced or metastatic solid tumors, including non small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, triple-negative breast cancer (TNBC), esophageal cancer, gastric cancer, cervical cancer, colorectal cancer (CRC), urothelial carcinoma (UC), clear cell renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Participants will be enrolled in 2 stages: dose escalation and dose expansion.`
    • Field `eligibilityModule.eligibilityCriteria` changed from `Inclusion Criteria:
      • Life expectancy at least 12 weeks
      • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
      • Measurable disease according to Response Evaluation criteria in Solid Tumors (RECIST) Version 1.1
      • Histologically confirmed locally advanced, recurrent, or metastatic incurable solid tumor malignancy
      • Tumor Specimen availability
    • Exclusion Criteria:
      • Pregnant or breastfeeding or intention of becoming pregnant during the study or within 4 months after the final dose of RO7501275, or 4 months after the final dose of pembrolizumab, or 5 months after the final dose of atezolizumab
      • Any anti-cancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to initiation of study treatment
      • Active hepatitis B or C or tuberculosis
      • Positive test for human immunodeficiency virus (HIV) infection
      • Acute or chronic active Epstein-Barr virus (EBV) infection at screening
      • Administration of a li` to `Inclusion Criteria:
      • Life expectancy of at least 12 weeks
      • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
      • Measurable disease according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
      • Histologically confirmed locally advanced, recurrent, or metastatic incurable solid tumor malignancy
      • Tumor specimen availability
    • Exclusion Criteria:
      • Pregnant or breastfeeding or intention of becoming pregnant during the study or within 4 months after the final dose of enzelkitug, or 4 months after the final dose of pembrolizumab, or 5 months after the final dose of atezolizumab
      • Any anti-cancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, and/or radiotherapy, within 3 weeks prior to initiation of study treatment
      • Active hepatitis B (HBV) or hepatitis C (HCV) or tuberculosis
      • Positive test for human immunodeficiency virus (HIV) infection
      • Acute or chronic active Epstein-Barr virus (EBV) infection at`
    • Field `outcomesModule.secondaryOutcomes.[0]` changed from `{'measure': 'Phase Ia and Phase Ib: Maximum Serum Concentration (Cmax) of RO7502175', 'timeFrame': 'From Cycle 1 (each cycle is 21 days) Day1 and at multiple timepoints up to each follow-up visits (up to approximately 5 years)'}` to `{'measure': 'Phase Ia and Phase Ib: Maximum Serum Concentration (Cmax) of Enzelkitug', 'timeFrame': 'From Cycle 1 (each cycle is 21 days) Day 1, and at multiple timepoints up to each follow-up visits (up to approximately 52 months)'}`
    • Field `armsInterventionsModule.armGroups.[2]` changed from `{'label': 'Phase Ib: Dose Escalation', 'type': 'EXPERIMENTAL', 'description': 'Participants in successive cohorts will receive escalating doses of RO7502175, as an IV infusion, in combination with a fixed dose of atezolizumab, as an IV infusion on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.', 'interventionNames': ['Drug: RO7502175', 'Drug: Atezolizumab']}` to `{'label': 'Phase Ib: Dose Escalation', 'type': 'EXPERIMENTAL', 'description': 'Participants in successive cohorts will receive escalating doses of enzelkitug, as an IV infusion, in combination with a fixed dose of atezolizumab, as an IV infusion on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.', 'interventionNames': ['Drug: Enzelkitug', 'Drug: Atezolizumab']}`
    • Field `armsInterventionsModule.interventions.[2]` changed from `{'type': 'DRUG', 'name': 'Pembrolizumab', 'description': 'Pembrolizumab will be administered as per the schedules specified in the respective arms.', 'armGroupLabels': ['Phase Ib: Expansion']}` to `{'type': 'DRUG', 'name': 'Pembrolizumab', 'description': 'Pembrolizumab will be administered as per the schedule specified in the respective arms.', 'armGroupLabels': ['Phase Ib: Expansion'], 'otherNames': ['Keytruda']}`
    • Field `armsInterventionsModule.armGroups.[1]` changed from `{'label': 'Phase Ia: Expansion', 'type': 'EXPERIMENTAL', 'description': 'Participants with select solid tumors will receive a recommended dose of RO7502175, determined in Phase Ia Dose Escalation phase as an IV infusion on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.', 'interventionNames': ['Drug: RO7502175']}` to `{'label': 'Phase Ia: Expansion', 'type': 'EXPERIMENTAL', 'description': 'Participants with select solid tumors will receive a recommended dose of enzelkitug, determined in Phase Ia dose escalation phase as an IV infusion on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.', 'interventionNames': ['Drug: Enzelkitug']}`
    • Field `outcomesModule.secondaryOutcomes.[2]` changed from `{'measure': 'Phase Ia and Phase Ib: Duration of Response (DOR)', 'timeFrame': 'From Cycle 1 (each cycle is 21 days) Day 1, until disease progression, death, or end of study (up to approximately 5 years)'}` to `{'measure': 'Phase Ia and Phase Ib: Duration of Response (DOR)', 'timeFrame': 'From Cycle 1 (each cycle is 21 days) Day 1, until disease progression, death, or end of study (up to approximately 52 months)'}`
    • Field `outcomesModule.secondaryOutcomes.[1]` changed from `{'measure': 'Phase Ia and Phase Ib: Objective Response Rate (ORR)', 'timeFrame': 'From Cycle 1(each cycle is 21 days) Day 1, until disease progression, death, or end of study (up to approximately 5 years)'}` to `{'measure': 'Phase Ia and Phase Ib: Objective Response Rate (ORR)', 'timeFrame': 'From Cycle 1(each cycle is 21 days) Day 1, until disease progression, death, or end of study (up to approximately 52 months)'}`
    • Field `outcomesModule.primaryOutcomes.[3]` changed from `{'measure': 'Phase Ib: Number of Participants with Treatment Emergent Adverse Events', 'timeFrame': 'Up to approximately 5 years'}` to `{'measure': 'Phase Ib: Number of Participants With TEAEs', 'timeFrame': 'Up to approximately 52 months'}`
    • Field `outcomesModule.primaryOutcomes.[2]` changed from `{'measure': 'Phase Ia: Number of Participants with Treatment Emergent Adverse Events', 'timeFrame': 'Up to approximately 5 years'}` to `{'measure': 'Phase Ia: Number of Participants With Treatment-emergent Adverse Events (TEAEs)', 'timeFrame': 'Up to approximately 52 months'}`
    • Field `armsInterventionsModule.interventions.[1]` changed from `{'type': 'DRUG', 'name': 'Atezolizumab', 'description': 'Atezolizumab will be administered as per the schedules specified in the respective arms.', 'armGroupLabels': ['Phase Ib: Dose Escalation', 'Phase Ib: Expansion']}` to `{'type': 'DRUG', 'name': 'Atezolizumab', 'description': 'Atezolizumab will be administered as per the schedule specified in the respective arms.', 'armGroupLabels': ['Phase Ib: Dose Escalation', 'Phase Ib: Expansion'], 'otherNames': ['Tecentriq']}`
    • Field `outcomesModule.secondaryOutcomes.[4]` changed from `{'measure': 'Phase Ia and Phase Ib: Percentage of Participants With Anti-Drug Antibody (ADA) to RO7502175', 'timeFrame': 'From Cycle 1 (each cycle is 21 days) Day 1 and at multiple timepoints up to tre
  • 2026-02-18 01:00:46 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-01` to `2026-02`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-01-16` to `2026-02-16`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-01-20` to `2026-02-17`
    • Field `contactsLocationsModule.locations.[22]city` changed from `N. Efkapria-Pavlos Melas` to `Pavlos Melas`
    • Field `contactsLocationsModule.locations.[30]facility` changed from `ICO l?Hospitalet ? Hospital Duran i Reynals` to `ICO Hospitalet- Hospital Duran i Reynals`

NCT06131398

  • 2026-05-29 03:42:23 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-12` to `2026-05`
    • Field `statusModule.primaryCompletionDateStruct.date` changed from `2026-05-24` to `2026-07-21`
    • Field `statusModule.completionDateStruct.date` changed from `2026-08-03` to `2026-07-21`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-12-19` to `2026-05-27`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-12-22` to `2026-05-28`

NCT06819735

  • 2026-05-26 02:38:39 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-03` to `2026-05`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-03-06` to `2026-05-04`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-03-10` to `2026-05-06`
    • Field `oversightModule.isFdaRegulatedDrug` changed from `False` to `True`
    • Field `contactsLocationsModule.locations.[5]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
  • 2026-03-11 02:05:41 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-11` to `2026-03`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-11-14` to `2026-03-06`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-11-18` to `2026-03-10`

NCT06911827

  • 2026-04-08 02:33:18 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-02` to `2026-04`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-02-24` to `2026-04-01`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-02-25` to `2026-04-07`
    • Field `designModule.enrollmentInfo.count` changed from `90` to `149`
  • 2026-02-26 00:55:48 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-03` to `2026-02`
    • Field `statusModule.overallStatus` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `statusModule.startDateStruct.date` changed from `2025-04` to `2025-05-09`
    • Field `statusModule.startDateStruct.type` changed from `ESTIMATED` to `ACTUAL`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-04-07` to `2026-02-24`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-04-09` to `2026-02-25`
    • New field added: `root['contactsLocationsModule']['locations']`

NCT05830045

  • 2026-07-28 00:26:03 (Trial Update)
    • Field `statusModule.overallStatus` changed from `RECRUITING` to `UNKNOWN`
    • New field added: `root['statusModule']['lastKnownStatus']`

NCT07011550

  • 2026-07-28 00:26:03 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-03` to `2026-07`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-03-17` to `2026-07-14`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-03-20` to `2026-07-15`
  • 2026-03-21 02:05:09 (Trial Update)
    • Field `statusModule.whyStopped` changed from `FDA` to `PI Request`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-03-10` to `2026-03-17`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-03-11` to `2026-03-20`
  • 2026-03-12 02:11:52 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-02` to `2026-03`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-02-20` to `2026-03-10`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-02-24` to `2026-03-11`
  • 2026-02-25 01:02:23 (Trial Update)
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-02-17` to `2026-02-20`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-02-19` to `2026-02-24`
    • Field removed: `root['statusModule']['expandedAccessInfo']`
  • 2026-02-20 00:56:09 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-08` to `2026-02`
    • Field `statusModule.overallStatus` changed from `RECRUITING` to `SUSPENDED`
    • Field `statusModule.startDateStruct.date` changed from `2025-11-30` to `2025-08-15`
    • Field `statusModule.startDateStruct.type` changed from `ESTIMATED` to `ACTUAL`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-08-20` to `2026-02-17`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-08-27` to `2026-02-19`
    • Field `designModule.enrollmentInfo.count` changed from `40` to `7`
    • Field `designModule.enrollmentInfo.type` changed from `ESTIMATED` to `ACTUAL`
    • New field added: `root['statusModule']['whyStopped']`
    • Field removed: `root['contactsLocationsModule']['centralContacts']`
    • Field removed: `root['contactsLocationsModule']['locations'][0]['status']`
    • Field removed: `root['contactsLocationsModule']['locations'][0]['contacts']`

NCT05101070

  • 2026-03-19 02:24:59 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-04` to `2026-03`
    • Field `statusModule.primaryCompletionDateStruct.date` changed from `2027-04-16` to `2028-05-31`
    • Field `statusModule.completionDateStruct.date` changed from `2027-04-16` to `2028-05-31`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-05-22` to `2026-03-16`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-05-28` to `2026-03-18`
    • Field `descriptionModule.briefSummary` changed from `The primary objective of Part A is to evaluate the safety and tolerability of S-531011 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of S-531011.
    • The primary objective of Parts B and C is to evaluate the antitumor activity of S-531011 at the RP2D.` to `The primary objective of Part A is to evaluate the safety and tolerability of S-531011 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of S-531011 with or without pembrolizumab.
    • The primary objective of Parts B and C is to evaluate the antitumor activity of S-531011 at the RP2D with or without pembrolizumab.
    • The primary objective of Parts D and E is to evaluate the antitumor activity of S-531011 at the RP2D in combination with bevacizumab with our without pembrolizumab.`
    • Field `designModule.enrollmentInfo.count` changed from `274` to `282`
    • Field `outcomesModule.secondaryOutcomes.[0]timeFrame` changed from `Every 6 weeks for the first 24 weeks and every 9 weeks thereafter, until disease progression (Approximately 12 months [Part A-1]; Approximately 24 months [Part A-2])` to `Every 6 weeks for the first 24 weeks and every 9 weeks thereafter, until disease progression (Approximately 12 months [Part A-1]; Approximately 24 months [Part A-2])`
    • Field `outcomesModule.secondaryOutcomes.[5]measure` changed from `Serum concentrations of S-531011` to `Parts B, C, D, E: Number of Participants with Treatment-emergent Adverse Events (TEAEs)`
    • Field `outcomesModule.secondaryOutcomes.[5]timeFrame` changed from `Part A: Cycle 1, Days 8 and 15 (4 hours post infusion); Cycles 2-9, Day 1 (pre- and end-of-infusion); Safety Follow-up Visit. Parts B and C: Day 1 of Cycles 1-9 (pre- and end-of-infusion); Safety Follow-up Visit. (each cycle is 21 days)` to `Approximately 12 months (Part B); Approximately 24 months (Parts C, D, E)`
    • Field `eligibilityModule.eligibilityCriteria` changed from `Key Inclusion Criteria:
      1. Male or female participant must be at least 18 years of age inclusive (or complies with country-specific regulatory requirements), at the time of signing the informed consent.
      1. Participants with histologically or cytologically confirmed advanced (locoregionally recurrent, not amenable to curative therapy) or metastatic solid tumors who have no standard therapies with a proven clinical benefit, or who are intolerant to or unwilling to receive these therapies for any reasons.
      1. Measurable disease by Response Evaluation Criteria in Solid Tumors version 1.1.
      1. (Part A only) Participants should have 1 of the following tumor types: malignant melanoma, head and neck squamous cell carcinoma, renal cell carcinoma, urothelial carcinoma, non-small cell lung cancer, or triple-negative breast cancer, esophageal cancer (esophageal squamous cell carcinoma and adenocarcinoma), or gastric cancer (gastric and gastroesophageal junction adenocarcinoma). Participants with colorectal cancer (CRC), pancreatic cancer, cervical cancer, epithelial ovarian cancer, and other types of solid tumors may also be enrolled upon discussion with and approval by the sponsor. For the backfill cohorts only, specific tumor types may be selected.
      1. (Part B CRC cohorts only) Participants must have histologically or cytologically confirmed adenocarcinoma of the colon or rectum, who had disease progression on or after receiving all of the following standard of care systemic therapies for advanced or metastatic disease or who were intolerant to: fluoropyrimidine, oxaliplatin, and irinotecan; anti-epidermal growth factor receptor (EGFR) therapy if rat sarcoma virus (RAS) (Kirsten RAS/neuroblastoma RAS \[KRAS/NRAS\]) wild-type; V-raf murine sarcoma viral oncogene homolog B (BRAF) inhibitor if BRAF V600E mutation. In addition, participants who received up to 2 additional lines of therapy for advanced or metastatic disease of the following therapies are also eligible: trifluridine/tipiracil, regorafenib, fruquintinib, other drugs approved in the country, or investigational drugs.
      1. (Part C CRC cohorts only) Participants must have histologically or cytologically confirmed adenocarcinoma of the colon or rectum, who had disease progression on or after receiving all of the following standard of care systemic therapies for advanced or metastatic disease or who were intolerant to: fluoropyrimidine, oxaliplatin, and irinotecan; anti-EGFR therapy if RAS (KRAS/NRAS) wild-type; BRAF inhibitor if BRAF V600E mutation. In addition, participants who received up to 2 additional lines of therapy for advanced or metastatic disease of the following therapies are also eligible: trifluridine/tipiracil, regorafenib, fruquintinib, other drugs approved in the country, or investigational drugs.
      1. Participants should be willing and able to provide permission to access archival formalin-fixed paraffin-embedded tumor tissues (as block or unstained slides) for this study.
      1. Participants should be willing and able to provide both pre-treatment and on-treatment paired tumor biopsy samples.
      1. (At selected sites only) Participants should be willing and able to provide both pre-treatment and on-treatment paired tumor biopsy samples. Fresh tissue samples are required as these will be used for the proof of mechanism (flow cytometry) analysis.
      1. Eastern Cooperative Oncology Group Performance Status of 0 or 1.
      1. An estimated life expectancy of at least 12 weeks.
      1. Adequate hematologic and organ function as confirmed by laboratory values.
      1. QT interval corrected with the Fridericia formula ≤ 480 milliseconds in 12-lead electrocardiogram at Screening.
    • Key Exclusion Criteria:
      1. Presence or history of autoimmune diseases or immune-mediated diseases that require chronic use of systemic corticosteroids (\> 10 milligrams of prednisone equivalent per day), immunosuppressive agents, or disease-modifying agents.
      1. Presence or history of interstitial lung disease and (non-infectious) pneumonitis that required corticosteroids.
      1. Active clinically significant bacterial, viral or fungal infection, or any major episode of infection requiring hospitalization or treatment with parenteral anti-infectives within 4 weeks before the first dose of study intervention.
      1. Uncontrolled or clinically significant cardiovascular disease defined as New York Heart Association classification III or IV.
      1. A positive test for hepatitis B surface antigen and/or hepatitis C virus (HCV) antibody (participants with positive HCV antibody are eligible if a confirmatory HCV RNA test is undetectable).
      1. A positive serological test for human immunodeficiency virus infection.
      1. Known history of any other relevant congenital or acquired immunodeficiency.
      1. Known history of an allogeneic tissue and/or solid organ transplant.
      1. Known history of severe allergy, hypersensitivity, anaphylaxis, or any serious adverse reaction to any component of study intervention or formulation components and/or any other monoclonal antibodies.
      1. Women who are pregnant or breastfeeding (or have discontinued breastfeeding) or trying to become pregnant.
      1. Clinical evidence of uncontrolled brain metastasis.
      1. Clinically uncontrollable symptomatic pleural effusion and/or ascites. (Participants who do not require fluid drainage or have no significant increase of fluid for 28 days may be eligible with approval by the sponsor.)
      1. Known additional malignancy that is progressing or has required active treatment within the past 3 years.
      1. (Part B and C CRC cohorts only): Colorectal cancer with mismatch repair deficient/microsatellite instability-high status.
      1. (Parts A-2 and C only): Has received prior therapy with an anti-programmed death 1, anti-programmed death ligand 1, or anti-programmed death ligand 2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (for example, cytotoxic T-lymphocyte-associated protein 4, OX-40, CD137), and was discontinued from that treatment due to ≥ Grade 3 immune-related adverse event.
      1. Prior treatment with systemic anticancer drugs (including any investigational medicinal products) within 28 days or 5 half-lives (whichever is shorter) before the first dose of study intervention.
      1. Prior major surgery within 28 days before the first dose of study intervention.
      1. Prior extended field radiotherapy within 28 days before the first dose of study intervention (within 14 days for limited field radiation for palliation) or history of radiation pneumonitis.
      1. Participants who have not recovered from any previous treatment toxicities to ≤ Grade 1 or baseline (except alopecia and peripheral neuropathy) before the first dose of study intervention.
      1. Prior treatment with anti-CCR8 antibody for any indication.
      1. Receipt of hematopoietic growth factors (for example, granulocyte-colony stimulating factor or erythropoietin) within 14 days before the first dose of study intervention or blood transfusions within 14 days before the first dose of study intervention.
      1. Receipt of a live, attenuated vaccine within 30 days before the first dose of study intervention.
    • Note: Additional inclusion/exclusion criteria may apply, per protocol.` to `Eligibility Criteria: Key Inclusion Criteria:
      1. Participants with histologically or cytologically confirmed advanced (locoregionally recurrent, not amenable to curative therapy) or metastatic solid tumors who have no standard therapies with a proven clinical benefit, or who are intolerant to or unwilling to receive these therapies for any reasons.
      1. Measurable disease by Response Evaluation Criteria in Solid Tumors version 1.1.
      1. (Part A only) Participants should have 1 of the following tumor types: malignant melanoma, head and neck squamous cell carcinoma, renal cell carcinoma, urothelial carcinoma, non-small cell lung cancer, or triple-negative breast cancer, esophageal cancer (esophageal squamous cell carcinoma and adenocarcinoma), or gastric cancer (gastric and gastroesophageal junction adenocarcinoma). Participants with colorectal cancer (CRC), pancreatic cancer, cervical cancer, epithelial ovarian cancer, and other types of solid tumors may also be enrolled upon discussion with and approval by the sponsor. For the backfill cohorts only, specific tumor types may be selected.
      1. (Part B CRC cohorts only) Participants must have histologically or cytologically confirmed metastatic adenocarcinoma of the colon or rectum, who had disease progression on or after receiving all of the following standard of care systemic therapies for advanced or metastatic disease or who were intolerant to: fluoropyrimidine, oxaliplatin, and irinotecan; anti-epidermal growth factor receptor (EGFR) therapy if rat sarcoma virus (RAS) (Kirsten RAS/neuroblastoma RAS \[KRAS/NRAS\]) wild-type and medically appropriate ; V-raf murine sarcoma viral oncogene homolog B (BRAF) inhibitor if BRAF V600E mutation. In addition, participants who received up to 2 additional lines of therapy for advanced or metastatic disease of the following therapies are also eligible: trifluridine/tipiracil, regorafenib, fruquintinib, other drugs approved in the country, or investigational drugs.
      1. (Part C CRC cohorts only) Participants must have histologically or cytologically confirmed metastatic adenocarcinoma of the colon or rectum, who had disease progression on or after receiving all of the following standard of care systemic therapies for advanced or metastatic disease or who were intolerant to: fluoropyrimidine, oxaliplatin, and irinotecan; anti-EGFR therapy if RAS (KRAS/NRAS) wild-type and medically appropriate ; BRAF inhibitor if BRAF V600E mutation. In addition, participants who received up to 2 additional lines of therapy for advanced or metastatic disease of the following therapies are also eligible: trifluridine/tipiracil, regorafenib, fruquintinib, other drugs approved in the country, or investigational drugs.
      1. (Parts D and E) Participants must have histologically or cytologically confirmed metastatic adenocarcinoma of the colon or rectum, who had disease progression on or after receiving all of the following standard of care systemic therapies for advanced or metastatic disease or who were intolerant to: fluoropyrimidine, oxaliplatin, and irinotecan; anti-EGFR therapy if RAS (KRAS/NRAS) wild-type and medically appropriate; BRAF inhibitor if BRAF-V600E mutation.. In addition, participants who received up to 2 additional lines of therapy for advanced or metastatic disease of the following therapies are also eligible: trifluridine/tipiracil, regorafenib, fruquintinib, other drugs approved in the country, or investigational drugs.
      1. Participants should be willing and able to provide permission to access archival formalin-fixed paraffin-embedded tumor tissues (as block or unstained slides) for this study.
      1. Participants should be willing and able to provide both pre-treatment and on-treatment paired tumor biopsy samples.
      1. (Part A and B/CRC Cohorts only; At selected sites only) Participants should be willing and able to provide both pre-treatment and on-treatment paired tumor biopsy samples. Fresh tissue samples are required as these will be used for the proof of mechanism (flow cytometry) analysis.
      1. Eastern Cooperative Oncology Group Performance Status of 0 or 1.
      1. An estimated life expectancy of at least 12 weeks.
      1. Adequate hematologic and organ function as confirmed by laboratory values.
      1. QT interval corrected with the Fridericia formula ≤ 480 milliseconds in 12- lead electrocardiogram at Screening.
    • Key Exclusion Criteria:
      1. Presence or history of autoimmune diseases or immune-mediated diseases that require chronic use of systemic corticosteroids (\> 10 milligrams of prednisone equivalent per day), immunosuppressive agents, or disease-modifying agents.
      1. Presence or history of interstitial lung disease and (non-infectious) pneumonitis that required corticosteroids.
      1. Active clinically significant bacterial, viral or fungal infection, or any major episode of infection requiring hospitalization or treatment with parenteral anti-infectives within 4 weeks before the first dose of study intervention.
      1. Uncontrolled or clinically significant cardiovascular disease defined as New York Heart Association classification III or IV.
      1. A positive test for hepatitis B surface antigen and/or hepatitis C virus (HCV) antibody (participants with positive HCV antibody are eligible if a confirmatory HCV RNA test is undetectable).
      1. A positive serological test for human immunodeficiency virus infection.
      1. Known history of any other relevant congenital or acquired immunodeficiency.
      1. Known history of an allogeneic tissue and/or solid organ transplant.
      1. Known history of severe allergy, hypersensitivity, anaphylaxis, or any serious adverse reaction to any component of study intervention or formulation components and/or any other monoclonal antibodies.
      1. Women who are pregnant or breastfeeding (or have discontinued breastfeeding) or trying to become pregnant.
      1. (Parts D and E only) Serious non-healing wound, non-healing ulcer, or non healing bone fracture.
      1. (Parts D and E only) Presence or history of severe arterial thromboembolic events (for example, cerebral infarction, transient ischemic attacks, myocardial infarction, and angina) within 6 months prior to the first dose of study intervention, and/or ≥ Grade 3 venous thromboembolic events (for example, deep vein thrombosis) within 3 months prior to the first dose of study intervention. Participants who receive a full-dose therapeutic anticoagulation should be excluded.
      1. (Parts D and E only) Known coagulopathy that increases risk of bleeding, bleeding diatheses, or any other hemorrhage/bleeding event of ≥ Grade 3 within 4 weeks prior to the first dose of study intervention.
      1. (Parts D and E only) Presence or history of any life-threatening vascular endothelial growth factor (VEGF)-related adverse event (AE).
      1. (Parts D and E only) Proteinuria ≥ 2+ by urine dipstick test within 4 weeks prior to the first dose of study intervention.
      1. Clinical evidence of uncontrolled brain metastasis.
      1. Clinically uncontrollable symptomatic pleural effusion and/or ascites. (Participants who do not require fluid drainage or have no significant increase of fluid for 28 days may be eligible with approval by the sponsor.)
      1. Known additional malignancy that is progressing or has required active treatment within the past 3 years.
      1. (Part B, C, D and E CRC cohorts only): Colorectal cancer with mismatch repair deficient/microsatellite instability-high status.
      1. (Parts A-2, C and E only): Has received prior therapy with an anti-programmed death 1, anti-programmed death ligand 1, or anti-programmed death ligand 2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (for example, cytotoxic T-lymphocyte-associated protein 4, OX-40, CD137), and was discontinued from that treatment due to ≥ Grade 3 immune-related adverse event.
      1. Prior treatment with systemic anticancer drugs (including any investigational medicinal products) within 28 days or 5 half-lives (whichever is shorter) before the first dose of study intervention.
      1. Prior major surgery within 28 days before the first dose of study intervention.
      1. Prior extended field radiotherapy within 28 days before the first dose of study intervention (within 14 days for limited field radiation for palliation) or history of radiation pneumonitis.
      1. Participants who have not recovered from any previous treatment toxicities to ≤ Grade 1 or baseline (except alopecia and peripheral neuropathy) before the first dose of study intervention.
      1. Prior treatment with anti-CCR8 antibody for any indication.
      1. Receipt of hematopoietic growth factors (for example, granulocyte-colony stimulating factor or erythropoietin) within 14 days before the first dose of study intervention or blood transfusions within 14 days before the first dose of study intervention.
      1. (Parts D and E only) Presence or history of allergic reactions or hypersensitivity to bevacizumab or any of its excipients.
      1. (Parts D and E only) Presence or history of hypersensitivity to Chinese Hamster Ovary cell products or other recombinant human or humanized antibodies.
      1. Receipt of a live, attenuated vaccine within 30 days before the first dose of study intervention.
    • Note: Additional protocol defined Inclusion/Exclusion criteria may apply.`
    • Field `contactsLocationsModule.locations.[0]status` changed from `RECRUITING` to `ACTIVE_NOT_RECRUITING`
    • Field `contactsLocationsModule.locations.[2]status` changed from `RECRUITING` to `ACTIVE_NOT_RECRUITING`
    • Field `armsInterventionsModule.interventions.[0]` changed from `{'type': 'DRUG', 'name': 'S-531011', 'description': 'Administered by intravenous infusion', 'armGroupLabels': ['Part A-1: S-531011 Monotherapy', 'Part A-2: S-531011 + Pembrolizumab', 'Part B: S-531011 Monotherapy', 'Part C: S-531011 + Pembrolizumab']}` to `{'type': 'DRUG', 'name': 'S-531011', 'description': 'Administered by intravenous infusion', 'armGroupLabels': ['Part A-1: S-531011 Monotherapy', 'Part A-2: S-531011 + Pembrolizumab', 'Part B: S-531011 Monotherapy', 'Part C: S-531011 + Pembrolizumab', 'Part D: S-531011 + Bevacizumab', 'Part E: S-531011 + Bevacizumab + Pembrolizumab']}`
    • Field `outcomesModule.primaryOutcomes.[1]` changed from `{'measure': 'Parts B and C: Objective Response Rate', 'timeFrame': 'Every 6 weeks for the first 24 weeks and every 9 weeks thereafter, until disease progression (Approximately 12 months [Part B]; Approximately 24 months [Part C])'}` to `{'measure': 'Parts B, C, D, E: Objective Response Rate', 'timeFrame': 'Every 6 weeks for the first 24 weeks and every 9 weeks thereafter, until disease progression (Approximately 12 months [Part B]; Approximately 24 months [Parts C, D, E])'}`
    • Field `outcomesModule.primaryOutcomes.[5]` changed from `{'measure': 'Parts B and C: Progression-free Survival', 'timeFrame': 'Every 6 weeks for the first 24 weeks and every 9 weeks thereafter, until disease progression (Approximately 12 months [Part B]; Approximately 24 months [Part C])'}` to `{'measure': 'Parts B, C, D, E: Progression-free Survival', 'timeFrame': 'Every 6 weeks for the first 24 weeks and every 9 weeks thereafter, until disease progression (Approximately 12 months [Part B]; Approximately 24 months [Parts C, D, E])'}`
    • Field `armsInterventionsModule.interventions.[1]` changed from `{'type': 'DRUG', 'name': 'Pembrolizumab', 'description': 'Administered by intravenous infusion', 'armGroupLabels': ['Part A-2: S-531011 + Pembrolizumab', 'Part C: S-531011 + Pembrolizumab'], 'otherNames': ['KEYTRUDA']}` to `{'type': 'DRUG', 'name': 'Pembrolizumab', 'description': 'Administered by intravenous infusion', 'armGroupLabels': ['Part A-2: S-531011 + Pembrolizumab', 'Part C: S-531011 + Pembrolizumab', 'Part E: S-531011 + Bevacizumab + Pembrolizumab'], 'otherNames': ['KEYTRUDA']}`
    • Field `outcomesModule.primaryOutcomes.[6]` changed from `{'measure': 'Parts B and C: Overall Survival', 'timeFrame': 'From first dose to death, or up to a maximum of 18 months after last dose in the last participant'}` to `{'measure': 'Parts B, C, D, E: Overall Survival', 'timeFrame': 'Every 6 weeks for the first 24 weeks and every 9 weeks thereafter, until disease progression (Approximately 12 months [Part B]; Approximately 24 months [Parts C, D, E])'}`
    • Field `outcomesModule.primaryOutcomes.[2]` changed from `{'measure': 'Parts B and C: Duration of Response', 'timeFrame': 'Every 6 weeks for the first 24 weeks and every 9 weeks thereafter, until disease progression (Approximately 12 months [Part B]; Approximately 24 months [Part C])'}` to `{'measure': 'Parts B, C, D, E: Duration of Response', 'timeFrame': 'Every 6 weeks for the first 24 weeks and every 9 weeks thereafter, until disease progression (Approximately 12 months [Part B]; Approximately 24 months [Parts C, D, E])'}`
    • Field `outcomesModule.primaryOutcomes.[3]` changed from `{'measure': 'Parts B and C: Disease Control Rate', 'timeFrame': 'Every 6 weeks for the first 24 weeks and every 9 weeks thereafter, until disease progression (Approximately 12 months [Part B]; Approximately 24 months [Part C])'}` to `{'measure': 'Parts B, C, D, E: Disease Control Rate', 'timeFrame': 'Every 6 weeks for the first 24 weeks and every 9 weeks thereafter, until disease progression (Approximately 12 months [Part B]; Approximately 24 months [Parts C, D, E])'}`
    • Field `outcomesModule.primaryOutcomes.[4]` changed from `{'measure': 'Parts B and C: Time to Response', 'timeFrame': 'Every 6 weeks for the first 24 weeks and every 9 weeks thereafter, until disease progression (Approximately 12 months [Part B]; Approximately 24 months [Part C])'}` to `{'measure': 'Parts B, C, D, E: Time to Response', 'timeFrame': 'Every 6 weeks for the first 24 weeks and every 9 weeks thereafter, until disease progression (Approximately 12 months [Part B]; Approximately 24 months [Parts C, D, E])'}`

NCT07362186

  • 2026-05-26 02:38:39 (Trial Update)
    • Field `statusModule.overallStatus` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `statusModule.startDateStruct.date` changed from `2026-04-03` to `2026-04-30`
    • Field `statusModule.startDateStruct.type` changed from `ESTIMATED` to `ACTUAL`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-01-15` to `2026-05-06`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-01-23` to `2026-05-11`
    • New field added: `root['contactsLocationsModule']['locations'][0]['status']`

NCT05537740

  • 2026-07-28 00:26:03 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-06` to `2026-07`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-06-18` to `2026-07-03`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-06-22` to `2026-07-07`
    • New field added: `root['contactsLocationsModule']['locations'][4]['state']`
    • New field added: `root['contactsLocationsModule']['locations'][5]['state']`
    • New field added: `root['contactsLocationsModule']['locations'][6]['state']`
  • 2026-06-24 14:19:39 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-05` to `2026-06`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-05-19` to `2026-06-18`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-05-20` to `2026-06-22`
    • New field added: `root['contactsLocationsModule']['locations'][12]['state']`
  • 2026-05-26 02:38:39 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-03` to `2026-05`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-03-19` to `2026-05-19`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-03-20` to `2026-05-20`
    • Field `contactsLocationsModule.locations.[14]state` changed from `Nouvelle-Aquitaine` to `New Aquitaine`
  • 2026-03-21 02:05:09 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-02` to `2026-03`
    • Field `statusModule.primaryCompletionDateStruct.date` changed from `2026-07-07` to `2027-04-30`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-02-20` to `2026-03-19`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-02-23` to `2026-03-20`
    • Field `contactsLocationsModule.locations.[20]facility` changed from `Clinica Universidad de Navarra | Pamplona | Oncologia` to `Clinica Universidad De Navarra | Pamplona | Oncologia`
    • Field `contactsLocationsModule.locations.[22]facility` changed from `Clinica Universidad de Navarra | Madrid | Oncologia` to `Clinica Universidad De Navarra | Madrid | Oncologia`
    • New field added: `root['contactsLocationsModule']['locations'][14]['state']`
    • New field added: `root['contactsLocationsModule']['locations'][13]['state']`
    • New field added: `root['contactsLocationsModule']['locations'][15]['state']`
    • New field added: `root['contactsLocationsModule']['locations'][16]['state']`
  • 2026-02-24 00:57:04 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-01` to `2026-02`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-01-21` to `2026-02-20`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-01-22` to `2026-02-23`
    • Field `contactsLocationsModule.locations.[20]facility` changed from `Clinica Universidad De Navarra | Oncologia Medica` to `Clinica Universidad de Navarra | Pamplona | Oncologia`
    • Field `contactsLocationsModule.locations.[22]facility` changed from `Clinica Universidad De Navarra | Oncologia Medica` to `Clinica Universidad de Navarra | Madrid | Oncologia`

NCT05007782

  • 2026-05-26 02:38:39 (Trial Update)
    • Field `contactsLocationsModule.locations.[25]city` changed from `Taoyuan` to `Taoyuan City`

NCT07205718

  • 2026-07-28 00:26:03 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-06` to `2026-07`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-06-12` to `2026-07-16`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-06-15` to `2026-07-17`
    • Field `contactsLocationsModule.locations.[3]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[6]contacts.[0]phone` changed from `314-747-7222` to `557-747-2115`
    • Field `contactsLocationsModule.locations.[6]contacts.[0]email` changed from `dadkins@dom.wustl.edu dadkins@im.wustl.edu` to `auberlec@wustl.edu`
    • Field `contactsLocationsModule.locations.[6]contacts.[1]name` changed from `Douglas Adkins` to `Christine Auberle`
    • Field `contactsLocationsModule.locations.[11]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
  • 2026-06-16 04:16:42 (Trial Update)
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-06-04` to `2026-06-12`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-06-05` to `2026-06-15`
    • Field `contactsLocationsModule.locations.[3]contacts.[0]email` changed from `vklam@jhmi.edu` to `ThoracicCancerTrials@jhmi.edu`
  • 2026-06-06 03:35:39 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-05` to `2026-06`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-05-20` to `2026-06-04`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-05-22` to `2026-06-05`
    • Field `contactsLocationsModule.locations.[0]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
  • 2026-05-26 02:38:39 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-03` to `2026-05`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-03-24` to `2026-05-20`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-03-25` to `2026-05-22`
    • Field `contactsLocationsModule.locations.[1]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[6]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[7]facility` changed from `Case Comprehensive Cancer Center` to `University Hospitals Cleveland Medical Center`
    • Field `contactsLocationsModule.locations.[8]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
  • 2026-03-26 02:29:47 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-02` to `2026-03`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-02-04` to `2026-03-24`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-02-06` to `2026-03-25`
    • Field `contactsLocationsModule.locations.[7]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[9]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`

NCT05635643

  • 2026-07-28 00:26:03 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-03` to `2026-07`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-03-17` to `2026-07-13`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-03-19` to `2026-07-14`
    • Field `contactsLocationsModule.overallOfficials.[0]name` changed from `Koho Izuka, MD` to `Study Director`
    • Field `contactsLocationsModule.overallOfficials.[0]affiliation` changed from `Coherus BioSciences` to `Coherus Oncology`
    • Field `contactsLocationsModule.locations.[0]status` changed from `RECRUITING` to `WITHDRAWN`
    • Field `contactsLocationsModule.locations.[1]status` changed from `RECRUITING` to `WITHDRAWN`
    • Field `contactsLocationsModule.locations.[3]status` changed from `RECRUITING` to `WITHDRAWN`
    • Field `contactsLocationsModule.locations.[5]status` changed from `RECRUITING` to `WITHDRAWN`
    • Field removed: `root['contactsLocationsModule']['locations'][0]['contacts']`
    • Field removed: `root['contactsLocationsModule']['locations'][1]['contacts']`
    • Field removed: `root['contactsLocationsModule']['locations'][3]['contacts']`
    • Field removed: `root['contactsLocationsModule']['locations'][5]['contacts']`
  • 2026-05-26 02:38:39 (Trial Update)
    • Field `referencesModule.references.[0]citation` changed from `Wang X, Kapoor VN, Chin DJ, Klakamp SL, Baruffaldi F, Mohan JF, Haines R, Dulak A, Panduro M, Ren Y, Masia R, Hill JA, LaVallee TM, Rajasekaran N. CHS-114: an afucosylated anti-CCR8 monoclonal antibody that selectively depletes intratumoral Treg cells and induces antitumor immune responses. Mol Cancer Ther. 2025 Dec 22. doi: 10.1158/1535-7163.MCT-25-0367. Online ahead of print.` to `Wang X, Kapoor VN, Chin DJ, Klakamp SL, Baruffaldi F, Mohan JF, Haines R, Dulak A, Panduro M, Ren Y, Masia R, Hill JA, LaVallee TM, Rajasekaran N. CHS-114: An Afucosylated Anti-CCR8 Monoclonal Antibody that Selectively Depletes Intratumoral Treg Cells and Induces Antitumor Immune Responses. Mol Cancer Ther. 2026 May 4;25(5):685-700. doi: 10.1158/1535-7163.MCT-25-0367.`
  • 2026-03-20 02:10:44 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-07` to `2026-03`
    • Field `statusModule.primaryCompletionDateStruct.date` changed from `2026-02` to `2026-09-30`
    • Field `statusModule.completionDateStruct.date` changed from `2026-02` to `2027-01-01`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-07-30` to `2026-03-17`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-08-01` to `2026-03-19`

NCT05935098

  • 2026-03-14 02:07:20 (Trial Update)
    • Field `identificationModule.organization.fullName` changed from `BeiGene` to `BeOne Medicines`
    • Field `statusModule.statusVerifiedDate` changed from `2025-06` to `2026-03`
    • Field `statusModule.overallStatus` changed from `ACTIVE_NOT_RECRUITING` to `TERMINATED`
    • Field `statusModule.primaryCompletionDateStruct.date` changed from `2027-03-31` to `2026-01-27`
    • Field `statusModule.primaryCompletionDateStruct.type` changed from `ESTIMATED` to `ACTUAL`
    • Field `statusModule.completionDateStruct.date` changed from `2027-03-31` to `2026-01-27`
    • Field `statusModule.completionDateStruct.type` changed from `ESTIMATED` to `ACTUAL`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-06-23` to `2026-03-11`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-06-25` to `2026-03-13`
    • Field `designModule.enrollmentInfo.count` changed from `263` to `99`
    • Field `designModule.enrollmentInfo.type` changed from `ESTIMATED` to `ACTUAL`
    • New field added: `root['statusModule']['whyStopped']`

NCT06657144

  • 2026-07-28 00:26:03 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-06` to `2026-07`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-06-10` to `2026-07-14`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-06-12` to `2026-07-15`
    • New field added: `root['contactsLocationsModule']['overallOfficials']`
  • 2026-06-13 03:52:39 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-04` to `2026-06`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-04-03` to `2026-06-10`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-04-06` to `2026-06-12`
    • Field `contactsLocationsModule.locations.[19]status` changed from `RECRUITING` to `WITHDRAWN`
    • Field removed: `root['contactsLocationsModule']['locations'][19]['contacts']`
  • 2026-05-26 02:38:39 (Trial Update)
    • Field `referencesModule.references.[0]citation` changed from `Wang X, Kapoor VN, Chin DJ, Klakamp SL, Baruffaldi F, Mohan JF, Haines R, Dulak A, Panduro M, Ren Y, Masia R, Hill JA, LaVallee TM, Rajasekaran N. CHS-114: an afucosylated anti-CCR8 monoclonal antibody that selectively depletes intratumoral Treg cells and induces antitumor immune responses. Mol Cancer Ther. 2025 Dec 22. doi: 10.1158/1535-7163.MCT-25-0367. Online ahead of print.` to `Wang X, Kapoor VN, Chin DJ, Klakamp SL, Baruffaldi F, Mohan JF, Haines R, Dulak A, Panduro M, Ren Y, Masia R, Hill JA, LaVallee TM, Rajasekaran N. CHS-114: An Afucosylated Anti-CCR8 Monoclonal Antibody that Selectively Depletes Intratumoral Treg Cells and Induces Antitumor Immune Responses. Mol Cancer Ther. 2026 May 4;25(5):685-700. doi: 10.1158/1535-7163.MCT-25-0367.`
  • 2026-04-07 02:32:47 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-03` to `2026-04`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-03-27` to `2026-04-03`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-03-31` to `2026-04-06`
    • Field `contactsLocationsModule.locations.[0]status` changed from `RECRUITING` to `WITHDRAWN`
    • Field removed: `root['contactsLocationsModule']['locations'][0]['contacts']`
  • 2026-04-01 02:42:41 (Trial Update)
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-03-25` to `2026-03-27`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-03-30` to `2026-03-31`

NCT07226856

  • 2026-06-10 03:50:43 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-12` to `2026-06`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-12-19` to `2026-06-05`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-12-22` to `2026-06-09`

📥 Download Full Data (CSV) 📥 Download Status Summary (CSV)

Monitoring Status

Trial ID Sponsor Update Status Conditions Phases Start End Enroll Last Updated
NCT04895709 Bristol-Myers Squibb Changed Recruiting Cervical Cancer, Gastric/Gastr… PHASE1 PHASE2 2021-05-27 2031-08-31 1,109 2026-06-29
NCT06479759 Shanghai Pulmonary Hospital, S… Changed Unknown NSCLC, PD-1 PHASE2 2024-01-12 2025-12-12 50 2024-06-24
NCT05518045 LaNova Medicines Limited No Change Active Not Recruiting Advanced Solid Tumor PHASE1 PHASE2 2022-08-26 2026-03-31 392 2026-02-01
NCT06873854 LaNova Medicines Limited No Change Not Yet Recruiting Advanced Solid Tumor PHASE2 2025-03-26 2030-01-26 84 2025-03-10
NCT06825494 Chia Tai Tianqing Pharmaceutic… No Change Recruiting Advanced Solid Tumor PHASE1 PHASE2 2025-04-08 2026-09 194 2025-12-10
NCT06821503 Chia Tai Tianqing Pharmaceutic… No Change Recruiting Advanced Pancreatic Cancer PHASE1 PHASE2 2025-04-11 2028-12 72 2026-03-06
NCT05255484 LaNova Medicines Limited No Change Terminated Advanced Solid Tumor PHASE1 PHASE2 2022-05-26 2023-10-06 24 2023-10-24
NCT05199753 LaNova Australia Pty Limited No Change Completed Advanced Solid Tumor PHASE1 PHASE2 2022-03-16 2024-12-31 78 2025-09-06
NCT05859464 Zai Lab (Hong Kong), Ltd. No Change Terminated Malignant Solid Tumor PHASE1 2023-07-24 2025-08-28 34 2025-10-14
NCT05005403 AbbVie No Change Recruiting Non-Small Cell Lung Cancer, He… PHASE1 2021-11-01 2027-07 694 2026-06-19
NCT05581004 Genentech, Inc. Changed Recruiting Locally Advanced or Metastatic… PHASE1 2022-10-20 2028-07-31 450 2026-07-03
NCT06131398 Amgen No Change Active Not Recruiting Advanced Solid Tumors PHASE1 2024-03-07 2026-07-21 77 2026-05-27
NCT05690581 Beijing InnoCare Pharma Tech C… No Change Recruiting Advanced Solid Tumors and Hema… PHASE1 2023-02-23 2026-02-28 146 2024-12-22
NCT06304571 HC Biopharma Inc. No Change Recruiting Advanced Solid Tumor PHASE1 2024-02-27 2026-07-16 76 2025-04-30
NCT06963814 HC Biopharma Inc. No Change Recruiting Advanced Cancer PHASE1 2025-07-04 2027-05-30 252 2025-07-14
NCT06819735 Domain Therapeutics Australia … No Change Recruiting Advanced Solid Tumors PHASE1 PHASE2 2025-06-25 2028-01 125 2026-05-04
NCT07213882 Assistance Publique - Hôpitaux… No Change Not Yet Recruiting Cutaneous T Cell Lymphoma (CTC… EARLY_PHASE1 2026-01-01 2028-08-01 30 2025-10-02
NCT06911827 Qilu Pharmaceutical Co., Ltd. No Change Recruiting Advanced Solid Tumor PHASE1 PHASE2 2025-05-09 2028-12 149 2026-04-01
NCT05830045 Qilu Pharmaceutical Co., Ltd. Changed Unknown Advanced Solid Tumors PHASE1 2023-05-19 2025-12-31 180 2024-06-25
NCT07011550 M.D. Anderson Cancer Center Changed Suspended Microsatellite-stable Colorect… PHASE2 2025-08-15 2030-07-01 7 2026-07-14
NCT05101070 Shionogi No Change Recruiting Solid Tumors PHASE1 PHASE2 2022-05-30 2028-05-31 282 2026-03-16
NCT07362186 LaNova Medicines Limited No Change Recruiting Locally Advanced or Metastatic… PHASE3 2026-04-30 2028-09-28 400 2026-05-06
NCT06387628 Fudan University No Change Recruiting TNBC - Triple-Negative Breast … PHASE2 2024-07-10 2027-04-01 74 2024-08-01
NCT05537740 Bayer Changed Active Not Recruiting Advanced Solid Tumors PHASE1 2022-10-11 2027-05-04 129 2026-07-03
NCT05007782 Gilead Sciences No Change Recruiting Advanced Solid Tumor PHASE1 2021-08-18 2028-12 416 2025-12-26
NCT07205718 Takeda Changed Recruiting Advanced or Metastatic Solid T… PHASE1 PHASE2 2025-11-19 2029-12-21 223 2026-07-16
NCT05635643 Coherus Oncology, Inc. Changed Recruiting Advanced Solid Tumor, Head and… PHASE1 2022-12-15 2027-01-01 87 2026-07-13
NCT05935098 BeiGene No Change Terminated Advanced Solid Tumor, Metastat… PHASE1 2023-08-21 2026-01-27 99 2026-03-11
NCT06657144 Coherus Oncology, Inc. Changed Recruiting Metastatic Solid Tumor, Advanc… PHASE1 2025-04-01 2028-01 154 2026-07-14
NCT06620822 Shanghai Pulmonary Hospital, S… No Change Not Yet Recruiting Non Small Cell Lung Cancer PHASE2 2024-09-30 2027-09-30 296 2024-09-28
NCT07226856 Mayo Clinic No Change Recruiting Metastatic Pancreatic Adenocar… PHASE2 2025-12-12 2028-12-01 43 2026-06-05
NCT04810572 University of Sao Paulo Genera… No Change Completed Insulin Resistance, Inflammato… NA 2021-05-20 2022-12-19 162 2024-01-30
NCT02836067 Boston Medical Center No Change Completed HIV, Smoking NA 2017-06-15 2023-12-31 53 2024-01-03
NCT07591597 National Cancer Center Hospita… No Change Not Yet Recruiting Metastatic Colorectal Neoplasm… PHASE1 PHASE2 2026-05 2029-05 68 2026-05-11
NCT07680764 Bristol-Myers Squibb No Change Recruiting Locally Advanced Non-Small Cel… PHASE2 2026-08-15 2030-09-15 160 2026-07-23